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Abstract 
Background The aim of the presented thesis was to analyze the activation of the monomeric 
G protein RhoA in adult cardiomyocytes and further to unravel the role of the guanine 
nucleotide exchange factor p63RhoGEF in this context. Previous data demonstrated that RhoA 
is activated in neonatal cardiomyocytes by GPCR ligands like endothelin-1 (ET-1), 
phenylephrine (PE) and angiotensin II (AngII). So far, a contribution of the Gq/11 protein-
regulated p63RhoGEF was demonstrated in the ET-1-mediated RhoA activation in neonatal 
cardiomyocytes. Moreover, RhoA was described to be permanently activated in pressure-
overloaded hearts and p63RhoGEF to be higher expressed in the same system. This led to 
the hypothesis that p63RhoGEF is involved in the GPCR-dependent RhoA regulation in adult 
cardiomyocytes. 
Methods The obtained data result from combined analysis of isolated wildtype (WT), healthy 
(sham) and diseased (transverse aortic constriction, TAC) adult mouse cardiomyocytes 
(AMCM) as well as of cholesterol-depleted AMCM (MβCD-AMCM) and of heterozygous (HET) 
and homozygous (KO) p63RhoGEF-knockout AMCM. p63RhoGEF-constructs were 
adenovirally overexpressed in WT-AMCM. The activity of RhoA was studied with the help of 
an antibody which specifically recognizes the conformation of active RhoA (RhoA-GTP) by 
immunofluorescence stainings and confocal imaging. Changes in RhoA activity were 
exemplarily confirmed by a biochemical binding assay. Protein distribution in AMCM was also 
analyzed by immunofluorescence stainings and confocal imaging, and protein expression was 
detected by immunoblot analysis. Quantitative analyses of protein co-localization and 
distribution were performed with ImageJ. 
Results Independent of the investigated condition, active RhoA was predominately localized 
at the sarcolemma in AMCM. Application of ET-1, PE and AngII to WT- or sham-AMCM resulted 
in an increased level of active RhoA and a redistribution towards the costameric regions of the 
sarcolemma. Neither in TAC-, MβCD-, HET- nor in KO-AMCM an activation occurred in 
response to the GPCR ligands. In contrast, in all four types of AMCM, ET-1 and PE reduced 
the RhoA activity compared to control. Interestingly, in TAC-, MβCD- and KO-AMCM the basal 
RhoA activity was increased indicating that the tight regulation of RhoA in its signal context is 
disturbed when i) the sarcolemma is disorganized as after TAC, ii) cholesterol is depleted after 
MβCD treatment, or iii) p63RhoGEF is fully absent. This prompted the idea that p63RhoGEF 
is not only involved in the activation of RhoA in response to GPCRs, but also important for the 
membrane homeostasis in AMCM. By overexpression of p63RhoGEF, we could confirm its 
formerly described localization at the sarcolemma and found in addition a perinuclear 
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distribution. This led amongst others to an increase in the number of cis-Golgi apparatus 
particles similar as observed in TAC-AMCM. In contrast, the loss of p63RhoGEF reduced 
particle number arguing that p63RhoGEF is involved in Golgi apparatus regulation. 
Interestingly, p63RhoGEF also affected the size of the AMCM nuclei. Overexpression of a 
dominant negative p63RhoGEF construct (p63∆N) reduced the area of the nuclei, comparable 
as seen in isolated AMCM and intact myocardium after p63RhoGEF depletion. Opposing to 
this, in TAC-AMCM the mean nucleus area was increased. This was in accordance with the 
observed changes in cell size. Although there were differences in the type and height of the 
affected parameters, p63RhoGEF-overexpression and TAC increased cell size, whereas 
p63RhoGEF depletion reduced it. 
Summary The presented data show for the first time that RhoA is activated in healthy adult 
cardiomyocytes in response to important cardiovascular GPCR ligands. Disturbances of the 
sarcolemmal organization ultimately lead to uncoupling of RhoA from its physiological signaling 
context. p63RhoGEF, verified as a direct mediator of the Gq/11 protein-dependent RhoA 
activation, plays an additional role in the regulation of RhoA and of membranous compartments 
in adult cardiomyocytes. Most importantly, its depletion leads to an uncoupling of RhoA from 
its signaling context. 
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1. Introduction 
1.1 Heart failure and cardiac remodeling 
According to the World Health Statistics 2017 of the World Health Organization (WHO), 17.7 
million people died of cardiovascular diseases in 2015, representing 31% of all global deaths. 
7.4 million of those patients suffered from coronary heart disease, which ultimately leads to 
heart failure (HF) and patients death [1]. 
In general, HF is defined as an abnormality of the cardiac structure or function leading to failure 
of the heart to deliver sufficient oxygen to the metabolizing tissues [2]. Clinically, HF has been 
defined by the European Society of Cardiology (ESC) in their Guidelines for the diagnosis and 
treatment of acute and chronic heart failure as "a clinical syndrome characterized by typical 
symptoms, e.g. breathlessness, ankle swelling and fatigue, that may be accompanied by signs 
like elevated jugular venous pressure, pulmonary crackles and peripheral oedema caused by 
a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output" [3]. HF 
can be caused by various diseases and risk factors such as chronic cardiac stress, pressure 
or volume overload, or injury caused by myocardial infarction or ischemia and by inherited 
diseases [4]. 
Parameters to quantify the left ventricular (LV) remodeling which accompanies HF 
development include heart size, shape and mass, ejection fraction, end-diastolic and end-
systolic volumes as well as peak force of contraction. However, HF is a disease of high 
complexity which cannot only be classified based on generalized values [5]. Nevertheless, 
reduced LV ejection fractions are usually associated with a poor prognosis in HF [6]. 
In 2000, a consensus paper in the Journal of the American College of Cardiology summarized 
the typical cardiac remodeling mechanisms occurring during the development of HF. According 
to this generalized overview, HF is characterized by genome expression, molecular, cellular 
and interstitial changes that result in changes of size, shape and function of the heart after 
cardiac injury [7]. 
On the organ level, the development of HF is accompanied by changes in geometry. After 
ischemic insults and due to volume overload, an eccentric hypertrophy can be observed. This 
means that the heart becomes less elliptical and more spherical with thinner walls [8]. On the 
other hand, pressure overload leads to a phenomenon known as concentric hypertrophy which 
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is characterized by an increased left ventricular wall thickness without or with less increase in 
chamber size [9]. 
At the cellular level, the main components of cardiac remodeling are: hypertrophy of 
cardiomyocytes [10], formation of fibrosis [11] characterized by an increased collagen content, 
proliferation of fibroblast [12] and apoptosis [13-15]. Upon an ischemic event, fibroblasts and 
endothelial cells are activated which leads to collagen synthesis and fibrosis [16]. In addition, 
collagenases are activated which might lead to an increase in ventricular chamber size and 
thereby to an impaired heart function [17, 18]. Furthermore, ongoing myocyte apoptosis also 
leads to a progressive left ventricular dysfunction [15]. The remodeling of cardiac myocytes 
will be discussed in detail in the next chapter. 
1.2 Cardiomyocytes: Structure, function and remodeling in disease 
The heart mainly consists of two different cell populations: the cardiomyocytes, represented 
with 30-35%, and non-cardiomyocytes [19]. Despite the relatively low percentage proportion, 
cardiomyocytes occupy 70% to 85% of the total volume of the heart [20]. These cells are 
required to generate the contractile force of the heart. Thus, they ensure blood perfusion of all 
organs and tissues and thereby their oxygen supply [21]. In the group of non-myocytes, 
endothelial cells with ~45% and fibroblasts with ~11% are the most abundantly represented 
cell types [22]. 
1.2.1 Cardiomyocyte membrane structures 
Adult cardiomyocytes are rod shaped, often binucleated and highly specialized cells with a 
complex architecture that allows an efficient and synchronous contraction of the cell [23]. Their 
cytoarchitecture is maintained by the cytoskeleton. The highly organized sarcomeres are 
laterally aligned and transduce mechanical signals. Between strictly ordered rows of contractile 
proteins forming the myofibrils, the sarcoplasmic reticulum (SR) and mitochondria cover about 
30% of the cell volume [24, 25]. 
The complex interplay between structures of the plasma membrane, which is called 
sarcolemma, the transverse tubules (TT), the SR and the sarcomere forms the basis for each 
contraction. TT are long membrane invaginations which provide the close proximity between 
the cell surface and the SR, the intracellular calcium store [26]. TT are 150 nm - 300 nm wide 
tube-like structures of the surface sarcolemma which are observed in myocytes from all 
mammalian species that have been studied so far. They form a network of transverse elements 
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penetrating the cell in regular intervals at the sarcomeric Z-lines and of longitudinal elements 
between the Z-lines [27, 28]. The TT membrane contains all major channel types that are 
important for heart function including L-type calcium channels, sodium channels, potassium 
channels and transporters like the Na+/Ca+ exchanger [29-33]. 
The cardiomyocyte surface membrane, sarcolemma as well as the TT are composed of 
proteins, cholesterol, glycero-, phospho-, and sphingolipids. Sphingolipids and cholesterol can 
laterally associate with each other and form so called lipid rafts [34, 35]. One class of lipid rafts, 
which play an important role in cardiac muscle, are caveolae. Caveolae are invaginations of 
the membrane with a flask-shaped structure and a diameter of 50 nm - 100 nm [36]. They are 
shaped and supported by caveolins [37]. Three different caveolin isoforms are currently known: 
caveolin-1, caveolin-2 and caveolin-3 [38]. Caveolin-3 has been shown to be essential for the 
formation of caveolae in myocytes [39]. Other studies also suggested the expression of 
caveolin-1 and caveolin-2 and their interaction with caveolin-3 in cardiomyocytes [40-43]. But 
there have also been opposing results indicating that caveolin-1 and -2 cannot be detected in 
ventricular myocytes [44, 45]. 
In contrast to the expression of caveolin-1 and -2 in cardiomyocytes, it is generally accepted 
that caveolae and caveolins participate in the organization of macromolecular complexes to 
ensure efficient signaling. Part of these complexes are, for example, G protein-coupled 
receptors, heterotrimeric G proteins, ion channels and a broad range of downstream signaling 
molecules [46, 47]. It has for example been shown that the localization of L-type calcium 
channels to a caveolar signaling complex is required for the β2-adrenergic regulation of the 
calcium inward current [48]. Furthermore, the important role of caveolae and compartmentation 
for signaling was impressively demonstrated by the treatment of NRCM with methyl-β-
cyclodextrin (MβCD) for cholesterol depletion. In this study, the caveolae- and stretch-
dependent activation of RhoA, a member of the Rho GTPases (which will be introduced in 
Chapter 1.4.1), and the transduction of mechanical force into signaling was shown to fail after 
disruption of the caveolae [49]. 
Besides the membrane systems which are important for organizing cardiomyocyte signaling 
and electromechnical coupling, the cells possess endomembranes engaged in secretory 
processes. Lipids and membrane proteins which are synthesized at the rough endoplasmic 
reticulum (rER), are transported to the plasma membrane via the Golgi apparatus. In contrast 
to other cells, like cardiac fibroblasts, the rER seems to be less extended in cardiomyocytes 
and mainly localized at the perinuclear region (reviewed in: Doroudgar et al.) [50]. Similar, the 
Golgi apparatus in adult cardiomyocytes is less extended and does not show the typical polarity 
and stack organization. In cardiomyocytes, Golgi apparatus speckles were found at the nuclear 
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poles representing the cis-part of the Golgi apparatus. The trans-Golgi apparatus compartment 
in contrast was described to be localized close to mitochondria and dispersed all over the cell 
[51]. 
1.2.2 Cardiomyocyte function 
In contrast to the other cell types in the heart, cardiomyocytes have the ability to translate 
electrical excitation into mechanical contraction; a process called excitation-contraction 
coupling [52]. 
With every single beat, the heart contracts (systole) and relaxes (diastole) to ensure the supply 
of the body with oxygen and nutrients. The repetitive contraction of the myocardium is initiated 
by the formation of an action potential (AP) in the sinoatrial node. The generated electrical 
impulse then spreads over the atrioventricular node, passing the bundles of His and the 
Purkinje fibers to propagate simultaneously over the ventricular myocardium and trigger the 
synchronous contraction [53]. 
The incoming cardiac AP initiates the excitation-contraction coupling. It activates and thus 
opens voltage-dependent L-type calcium channels. The cytosolic influx of calcium (Ca2+) into 
the dyadic space triggers the release of large amounts of Ca2+ from the SR via the Ca2+ release 
ryanodine receptor channel (calcium-induced calcium release). The SR represents the 
intracellular Ca2+ storage. The dyadic space, which is formed by the close association (~15 nm) 
of L-type Ca2+ channels in the TT and ryanodine receptors in the SR, ensures a spatially and 
temporally synchronous and fast Ca2+ release [54]. The large amount of Ca2+ released into the 
cytosol from the SR binds to troponin C. This leads to a conformational change and thus to the 
release of the actin-inhibiting troponin I. As a result, cross-bridges are formed between actin 
and myosin under ATP hydrolysis [55]. For relaxation of the cardiomyocyte in diastole, the 
cytosolic Ca2+ is recycled via the sarco-endoplasmic reticulum Ca2+ transporter (SERCA) into 
the SR and a smaller amount is removed from the cytosol into the extracellular space via the 
Na+/Ca2+ exchanger (NCX) [56]. 
1.2.3 Remodeling of cardiomyocytes in disease 
In response to various pathological stimuli, cardiomyocytes often undergo hypertrophy. In early 
pathological stages this hypertrophic growth is usually protective because it allows the heart 
to generate sufficient contractile force. However, ongoing hypertrophic growth often leads to 
HF [21]. As previously mentioned, HF is a disease which is characterized by the reduced 
contractile capacity of the heart. This is in part due to a disturbed function of the 
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cardiomyocytes. Factors being involved in the reduced contractile capacity of the cell are for 
example remodeling of the sarcolemma and thereby defective cardiomyocyte Ca2+ handling. 
As previously described, an intact TT-system is necessary for functional Ca2+ handling since 
the close proximity of L-type Ca2+ channels and ryanodine receptors ensures a synchronous 
Ca2+ release. Therefore, TT remodeling can lead to changes in the dyadic space and thereby 
to an unregulated and asynchronous Ca2+ release which contributes to the contractile 
dysfunction in failing hearts. It has been shown that, as a consequence of TT-remodeling, a 
reduced Ca2+ release synchronicity results in increased time to reach the Ca2+ release peak, 
to lower intracellular Ca2+ concentrations and finally to decreased contraction force. [57-59]. 
Several other studies pointed out that remodeling of the cardiomyocyte membrane network 
and TT plays an important role during the development of HF and in terminally failing hearts 
[57, 60]. Additionally, the close connection between TT, signaling molecules and caveolin-3 in 
failing hearts was demonstrated by the overexpression of caveolin-3 in failing cardiomyocytes. 
As a result, the disordered localization of β2-adrenergic receptors could be restored by 
overexpression of caveolin-3 [61]. 
On top of the broad field of changes in the cardiomyocyte membrane structures of failing 
hearts, also morphological changes of the Golgi apparatus were reported which had an 
influence on its central role in protein processing and secretion pathways. These changes 
included an increase in size and complexity together with the development of hypertrophy and 
hyperplasia of the Golgi apparatus [62-64]. Finally, in addition to the previously described 
severe changes, diseased cardiomyocytes showed strong remodeling of the highly organized 
sarcomere, characterized by increased viscosity and stiffness resulting in reduced contractility 
[65, 66]. 
1.3 G protein-coupled receptor signaling in cardiomyocytes  
G protein-coupled receptors (GPCRs) are located in the plasma membrane of all cells. They 
represent direct targets of over a third of the currently approved cardiovascular drugs [67, 68]. 
This already indicates that GPCRs play a very important role in cardiac health and disease. 
All GPCRs possess seven membrane-spanning α-helical segments separated by alternating 
intracellular and extracellular loop regions [69]. Upon binding of a ligand to the extracellular 
side of the GPCR, a conformational change leads to interaction and dissociation of the 
intracellularly coupled heterotrimeric guanine nucleotide regulatory proteins (G proteins) [70-
74]. As indicated by their name, heterotrimeric G proteins consist of three subunits: α, β and 
γ. Upon activation of a GPCR by a specific ligand, GDP, which is bound by the inactive G 
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protein, is released from the α-subunit allowing GTP to enter the binding pocket. This induces 
a conformational change which results in the dissociation of the Gα and Gβγ subunits leading 
to the activation of specific downstream signal mediators [75, 76]. The major GPCR targets in 
the treatment of HF are the catecholamine-activated β-adrenoceptors and the angiotensin II 
type 1 receptor (AT1R) [77, 78]. 
1.3.1 β-adrenergic receptors in health and disease 
Adrenergic receptors play an important role in the translation of signals from the sympathetic 
nervous system to the cardiovascular system. At present, β-adrenergic receptors (β-AR) of the 
subtypes β1, β2 and β3 are distinguished. In the healthy heart, signaling by β1- and β2-AR is 
coupled primarily to stimulatory G proteins (Gs) which activate adenylyl cyclases and thereby 
increase the level of cyclic adenosine monophosphate (cAMP) to regulate heart rate and 
contractility [79, 80]. The identified coupling of β2-AR to inhibitory G proteins (Gi) has been 
shown to have deleterious effects, potentially through the negative regulation of Ca2+ dynamics 
by the reduced phosphorylation of troponin I and phospholamban [81]. This unusual coupling 
results from phosphorylation of the β2-AR by protein kinase A (PKA). During HF, chronic 
catecholamine stimulation leads to a change in the ratio between β1-AR and β2-AR from 80:20 
in healthy hearts to 60:40 in failing hearts. In addition, and as a consequence of chronic 
stimulation, the heart develops hypertrophy and apoptosis of the myocytes accompanied by 
contractile dysfunction [82, 83]. β3-AR can couple to both, Gs and Gi proteins [84]. In the human 
heart, β3-AR-mediated Gi signaling has a negative inotropic effect which could be involved in 
pathophysiological mechanism leading to HF [85]. Additionally, for transgenic mice with cardiac 
overexpression of human β3-AR coupled to Gs proteins, a positive inotropic effect has been 
shown [86]. 
In 2010, a study by Nikolaev et al. used a combination of live-cell scanning ion conductance 
microscopy (SICM) and a specifically designed cAMP FRET sensor to show that β-receptors 
are significantly redistributed in diseased cardiomyocytes. The authors found that in healthy 
myocytes, β2-AR induced cAMP signals were localized exclusively to the TT while β1 
adrenergic receptors were distributed across the entire cell surface. In myocytes from rats with 
chronic HF, β2-AR were redistributed from the TT to the sarcolemma, leading to diffuse cAMP 
signaling which could potentially contribute to the failing myocardial phenotype [87]. In addition, 
Gorelik and colleagues could show that caveolin-3 (which has been introduced in Chapter 
1.2.1) plays a crucial role for the localization of β2-AR and compartmentation of β2-AR-cAMP 
signaling to the TT of isolated healthy adult rat ventricular myocytes [61]. 
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1.3.2 Angiotensin II receptors in health and disease 
Angiotensin II receptors are activated by angiotensin II (AngII) which for example regulates 
cardiac contractility and is involved in cardiac remodeling, growth and apoptosis [88]. 
Angiotensin receptor blockers and angiotensin-converting enzyme (ACE) inhibitors are 
commonly used to reduce cardiac hypertrophy, to slow the progression of HF and to improve 
survival in HF patients [84]. Angiotensin II signals are primarily transferred via the Gq-coupled 
angiotensin II type 1 receptor (AT1R) [89]. Receptor signaling via Gq/11 proteins leads to 
stimulation of phospholipase Cβ (PLCβ) which hydrolyzes phosphatidylinositol 4,5 
biphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). 
Subsequently, DAG for example activates protein kinase C (PKC) which is important for 
myocyte apoptosis, and for the activation of hypertrophic gene transcription [90, 91] 
Both, up- and downregulation of AT1R have been reported in cardiovascular diseases. AT1R 
has been shown to be upregulated in hypertrophy and ischemia [92-94]. In human patients 
with end-stage HF, AT1R has been shown to be downregulated [95, 96]. 
1.4 RhoGTPases 
The family of monomeric Rho guanosine triphosphate hydrolases (GTPases) belongs to the 
Ras superfamily of G proteins, which in humans is represented by more than 150 proteins. 
The GTPases with a molecular weight of 20 kDa to 40 kDa can be divided into 5 subfamilies 
whose other members besides Ras are Rho, Rab, Ran and ARF [97]. Common to all members 
of the family is the presence of a conserved N-terminally located G box, consisting of the 
regions G1 to G5. Those regions are important for the conformational change that is induced 
by the binding of GTP or the hydrolysis of GTP to GDP [98]. 
The Rho GTPase family consists of 20 members with a detailed classification into 8 
subfamilies, of which five are typical GTPases and three are atypical GTPases. Atypical Rho 
GTPases differ from the typical ones in having a modification at the guanosine 
triphosphate/guanosine diphosphate (GTP/GDP) binding region [99]. In line with other 
GTPases, the typical Rho GTPases act as molecular switches cycling between an active GTP-
bound and an inactive GDP-bound state [100]. The activation of Rho GTPases can be 
regulated by a variety of up-stream signal mediators, including GPCRs, adhesion receptors 
like integrins, cytokines and tyrosine kinase [101, 102]. 
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Besides the activation through binding of GTP, Rho GTPase signaling is regulated by three 
additional types of proteins: Guanine nucleotide exchange factors (GEFs), GTPase activating 
proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs). The relatively slow 
dissociation of GDP and the resulting activation by binding of GTP is accelerated by GEFs. 
The inactivation and associated GTP to GDP hydrolysis is accelerated by GAPs [103]. In 
addition to the switch between active and inactive Rho GTPases, it was shown that binding of 
GDIs leads to an inhibition of the release of GDP/GTP and an associated retention in the 
cytosol instead of a translocation to the membrane [104, 105]. 
1.4.1 RhoA activation 
RhoA, a small GTPase, belongs to the previously described Ras superfamily and in detail to 
the subfamily of Rho GTPases. RhoA is one of the most extensively studied members of Rho 
GTPases besides Rac1 and Cdc42. Initially, RhoA was investigated in swiss 3T3 fibroblasts 
by Ridley and Hall in 1992. By extracellular stimulation with growth factors, this study showed 
an association of RhoA with the formation of actin stress fibers and focal adhesions [106]. 
As described earlier for Rho GTPases in general, RhoA cycles between an active GTP-bound 
and inactive GDP-bound state [103]. This activation is catalyzed by various GEFs. The catalytic 
DH domain (Dbl homologous domain) of the GEFs, specifically the segments α1, α5, and α6, 
forms a stable nucleotide free complex with the switch 1 and switch 2 region of RhoA. In this 
conformation the GDP/GTP exchange can take place and RhoA becomes active. Active RhoA 
is predominately located at the plasma membrane [107]. 
As mentioned before, the activity of GTPases is also regulated by RhoGDIs. In the case of 
RhoA it has been shown that C-terminal post-translational modifications such as isoprenylation 
and phosphorylation can alter both localization and activity. Upon isoprenylation of the C-
terminus, RhoA localizes to the membrane and free diffusion through the cytoplasm is 
prevented, thereby also affecting its activity because the regulating RhoGEFs are also 
localized to the membrane [108]. On the other hand, lipid modifications also serve to regulate 
activity through RhoGDIs. Through interaction with lipid modifications, RhoA is released from 
the membrane and diffuses through the cytosol [109-111]. Phosphorylation of RhoA by the 
cAMP-dependent protein kinase A (PKA), has been shown to result in an enhanced interaction 
with RhoGDIs. As a consequence, phosphorylated RhoA complexes with the RhoGDIs which 
provides a further mechanism for regulation of activity besides GDP/GTP cycling [112, 113]. 
Of special importance for the heart is the activation of RhoA by GPCRs. Here, GPCRs which 
couple to the G protein subfamilies Gq/11 and G12/13 are best investigated including the α-
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adrenoceptors and endothelin-1 receptors. These G protein subfamilies had been 
demonstrated to interact with and to activate a subset of RhoGEFs directly leading to RhoA 
activation. For G12/13 proteins, the three GEFs p115RhoGEF, PDZRhoGEF, leukemia-
associated RhoGEF (LARG, RhoGEF12) are well described to activate RhoA in diverse cell 
types. In cardiomyocytes, a contribution of p115RhoGEF and LARG in GPCR-induced 
signaling has been demonstrated so far [114, 115]. Gq/11 protein-dependent RhoA activation is 
mediated by a different subset of RhoGEFs. This includes p63RhoGEF, kalirin and Trio [116]. 
Amongst these, p63RhoGEF is the best characterized in the context of GPCR signaling and is 
described below in more detail. 
1.4.2 RhoA in diseased cardiomyocytes 
Early studies in neonatal cardiomyocytes suggested that RhoA is involved in pro-hypertrophic 
processes. RhoA was found to regulate the expression of hypertrophy-associated genes like 
the atrial natriuretic peptide (ANP) and to control myofibrillogenesis [117, 118]. In accordance, 
RhoA was activated downstream of hypertrophy-inducing GPCRs including endothelin-1-, 
angiotensin II type I and α-adrenergic receptors [117-119]. Moreover, Del Re et al. 
demonstrated by adenoviral overexpression of active RhoA in neonatal rat cardiomyocytes 
(NRCM), on the one hand the induction, on the other hand the protection from apoptosis. As a 
result of the high level expression of active RhoA, hypertrophy was induced in cardiomyocytes 
which in further progression led to apoptosis. The reason was caspase-9 activation and 
nucleosomal DNA fragmentation. [120]. On the other hand, the authors showed that moderate 
chronic RhoA activation in cardiomyocytes could protect against the apoptotic effects induced 
by H2O2, glucose deprivation and stretch. [121]. 
This ambivalent role of RhoA in cardiomyocytes was further supported by genetic mouse 
models. Constitutive overexpression of wild type RhoA in cardiomyocytes increased ANP 
expression and let to atrial hypertrophy whereas the left ventricle was dilated and fibrotic. The 
contractile function was impaired, the heart rate reduced, and AV blocks occurred. The overall 
mortality was strongly increased. These effects were gene dose dependent [122]. By a 
conditional model, it could be shown that only when constitutively active RhoA is expressed 
during development, cardiac hypertrophy occurred in adulthood. In mice starting to 
overexpress active RhoA at 3 weeks of age, no hypertrophy and fibrosis were detectable. 
Instead, mice exposed to ischemia/reperfusion (I/R) injury with increased expression of active 
RhoA showed increased tolerance to I/R with reduced myocardial infarct sizes due to an 
unexpectedly increased activity of protein kinase D [123]. 
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To investigate the opposite approach, the cardiomyocyte-specific deletion of RhoA in 
combination with transverse aortic constriction (TAC) or I/R injury was investigated. The 
absence of RhoA in cardiomyocytes had no effect on functional and structural properties. Also, 
a comparable development of hypertrophy induced by pressure overload was observed. After 
long term TAC, the influence of the absent RhoA changed impressively. The hearts showed 
more pronounced dilations with increased chamber sizes and limited contractile function 
(dilated cardiomyopathy, acceleration of HF). Also for I/R injury, the model showed less 
tolerance to the intervention, which was reflected by enlarged infarct sizes. The 
pathophysiological effects of the TAC intervention were reflected by impaired Ca2+ signaling 
and decreased activity of extracellular signal-regulated kinase 1 and 2 (ERK 1/2) and AKT. In 
contrast to those deleterious effects, hearts from mice with the cardiomyocyte-specific RhoA 
deficiency showed less fibrosis, indicating that RhoA mediates both, cardio-protective and 
cardio-deleterious effects [123, 124].  
Various approaches investigated the impact of total RhoA in different disease models, such as 
TAC and I/R, over a period of eight to ten weeks. Deviating from this, Takefuji et al. investigated 
the changes in the ratio of active RhoA to total RhoA for short term (24 to 72 hours), middle 
term (4 weeks) and long term (1 year) periods after the TAC intervention. In that study, a rapidly 
increased and preserved activation of RhoA together with a constant amount of total RhoA was 
shown for short term and middle term. One year after the TAC intervention, there was still a 
significant increased ratio of active RhoA to total RhoA [114]. Likewise, in human hearts from 
patients with congestive heart failure, RhoA activity was shown to be up-regulated [125]. 
Taken together, previous studies imply a beneficial role for low levels of active RhoA during the 
onset of cardiovascular diseases, but a detrimental role of high amounts of RhoA under basal 
conditions. Moreover, the loss of RhoA in diseased cardiomyocytes was found to be protective 
and deleterious at the same time. 
1.5 Rho guanine nucleotide exchange factors (RhoGEFs) 
The human genome encodes for 82 RhoGEFs divided into two families. The smaller family of 
DOCK (dedicator of cytokinesis related proteins) consists of 11 members [126] whereas the 
larger family with 71 protein members is represented by the Dbl (diffuse B-cell lymphoma)-like 
family [127]. 
In 1985, eponymous for the Dbl-like family, the first mammalian GEF Dbl was isolated. Dbl is 
a human oncogenic protein that has been isolated from diffuse B-cell lymphoma and was 
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subsequently shown to have a sequence homology of approximately 180 amino acids with the 
Rho family guanine nucleotide exchange factor CDC24 in yeast [128]. Furthermore, the 
catalytic activity of this domain for GDP dissociation and nucleotide exchange on human Cdc42 
was shown [129]. This led to the identification of the conserved Dbl homology (DH) domain, 
which can be found in all RhoGEFs other than DOCK proteins [130]. 
By binding of the DH domain to the GDP bound Rho GTPase, a conformational change occurs 
and GDP is released. Due to the stabilization of the high affinity intermediate and the cellular 
favorable ratio of GTP to GDP (~10:1), GTP can rapidly bind to the RhoGTPase [131]. The 
specificity of individual GEFs for the Rho GTPases in signaling is determined by their sequence 
as well as by spatial and temporal locations in combination with membrane 
compartmentalization in the cell [132, 133]. 
Common to all RhoGEFs of the Dbl-like subfamily is the pleckstrin homology (PH) domain 
which directly follows the DH domain. Both together form an invariant tandem which serves as 
a minimal unit. The PH domain consists of 100 to 120 amino acids, often being found in 
proteins involved in signaling with localization close to the membrane [134]. The PH domain 
can influence the activity and localization of the GEF in the cell. RhoGEFs with a missing PH 
domain can show a lower or higher nucleotide exchange activity compared to RhoGEFs with 
the complete DH-PH tandem motif [135, 136]. The increase in activity might result from the 
relieve of an autoinhibitory constraint [137]. Furthermore, with the help of the PH domain, 
RhoGEFs of the Dbl family bind to phosphoinositide, thus supporting their localization to the 
membrane, but without an effect on the catalytic activity [138]. 
1.5.1 p63RhoGEF structure and signaling 
p63RhoGEF was first investigated in 2001 by Souchet and colleagues in human heart and 
brain tissue [139]. The nucleotide exchange factor has a size of 63 kDa with 580 amino acids 
and is encoded by the gene ARHGEF25. Due to its main structural feature, the DH-PH tandem 
motif, p63RhoGEF is a member of the Dbl-like family. In contrast to other multi-domain GEFs, 
p63RhoGEF does not possess any other domains than the minimal unit. The N- and C-terminal 
sequences are largely unstructured [116]. The ability of p63RhoGEF to activate RhoA is without 
doubt and has been demonstrated by different groups [139-141]. However, there is still a 
debate whether p63RhoGEF or its N-terminally truncated splice variant GEFT, missing the first 
106 amino acids, can activate Rac1 and CDC42 [140, 142]. In addition to p63RhoGEF and 
GEFT, an additional longer variant with 618 (mouse) or 619 (human) amino acids and a 
different N-terminus was identified. For this variant either only Rac1 and CDC42, but no RhoA 
activation [142] or RhoA and Cdc42, but no Rac1 activation was demonstrated [143]. Whether 
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or not p63RhoGEF and its variants context-wise activate different RhoGTPases needs to be 
investigated further. However, based on genome analysis it is clear that there is only one 
ARHGEF25 gene which gives rise to several splice variants [141, 143, 144]. 
Consistent with other GEFs, the DH domain of p63RhoGEF exerts the catalytic activity for the 
exchange of GDP to GTP for RhoGTPases, whereas the PH domain is responsible for the 
regulation of its activity. The PH domain acts on the one hand as an inhibitor for the DH domain 
and serves on the other hand as binding site for active Gαq/11 subunits of heterotrimeric G 
proteins. Thus, by interaction of the Gαq/11 subunits with a conserved amphipathic helical 
extension of the PH domain and by the resulting conformational change, the autoinhibition is 
abolished [116, 137, 145]. As p63RhoGEF shows no other domains apart from the tandem 
motif, all variants of p63RhoGEF are likely to represent a direct link between GPCRs, the 
subsequent heterotrimeric G proteins, and RhoA. In line with this hypothesis, an N-terminally 
truncated version of p63RhoGEF, representing the sequence of GEFT, was sufficient to 
augment GPCR-driven RhoA and SRF activation [116]. In contrast to other RhoGEFs whose 
localization is altered by modifications of the PH domain, p63RhoGEF was found to be 
palmitoylated at a cysteine stretch in the N-terminus, which confines its permanent localization 
at the plasma membrane. In contrast, the long human 619 amino acid p63RhoGEF as well as 
GEFT cannot be palmitoylated due to the differences in the N-termini and are localized in the 
cytosol under basal conditions. However, in response to activation both variants were 
translocated to the plasma membrane and transported back into the cytosol when the signal 
ended [136, 143, 146].  
Although, p63RhoGEF was primarily detected by Northern blot analysis in human heart and 
brain tissue, its expression seems to be less restrictive as initially supposed [139, 144]. Since 
then, the protein has been detected in different other cell types including cancer cells [147], 
osteoblasts [148], vascular smooth muscle cells [149, 150] and cardiac fibroblasts [151]. 
However, so far no extensive localization studies of the endogenous protein are available, 
likely due to the lack of appropriate antibodies. Interestingly, with two different non-
commercially available antibodies two independent groups demonstrated its localization in 
adult heart tissue. Souchet and colleagues suggested that p63RhoGEF mainly resides in the 
I-band of the sarcomere, whereas Smith and colleagues found a strong sarcolemmal and a 
minimal sarcomeric localization [139, 142]. 
The role of p63RhoGEF in the cardiovascular system has been mainly unraveled for vascular 
smooth muscle cells so far. In rat aortic smooth muscle cells, it was shown that p63RhoGEF 
is an important mediator of the angiotensin-II dependent RhoA activation and that it triggered 
cellular processes, such as proliferation and contraction [150]. In portal veins, p63RhoGEF 
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was demonstrated to be involved in the endothelin-1 and phenylephrine induced contraction 
[149]. These data suggest that p63RhoGEF is involved in the regulation of vascular 
contractility. However, p63RhoGEF levels were in addition found to be increased in 
mononuclear cells of hypertensive patients and reduced after treatment with the AT1R 
antagonist Olmesartan indicating that this GEF could play a more general role in 
cardiovascular diseases like hypertension [152, 153]. 
Our group investigated p63RhoGEF signaling in cardiac fibroblasts. We could show that 
p63RhoGEF is upregulated in hearts from mice that had been subjected to a TAC intervention. 
In 2D cell culture experiments with neonatal rat cardiac fibroblasts we found a prominent AngII-
dependent RhoA activation through p63RhoGEF. In addition, 3D engineered heart muscle 
(EHM) was used to investigate the effects of fibroblasts overexpressing p63RhoGEF or 
expressing a dominant negative p63RhoGEF version (p63ΔN). While p63RhoGEF expression 
in cardiac fibroblasts increased EHM resting and twitch tensions, fibroblasts expressing the 
dominant negative version decreased both, resting and twitch tension. Confocal microscopy 
experiments revealed the localization of full length p63RhoGEF in the vicinity of WGA-positive 
membranes and to the trans-Golgi membrane network of cardiac fibroblasts. In contrast, 
p63ΔN was mainly located in the cytosol of cardiac fibroblasts [151]. 
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2. Previous results and aims of the project 
The nucleotide exchange factor p63RhoGEF was identified by Souchet et al. in 2001, being 
expressed in human heart and brain tissue [139]. Further studies demonstrated its function as 
a direct mediator of the Gq/11 protein-dependent RhoA activation in different cell types [116, 
149, 150, 154]. However, until now its role for the function of the most important cell type in the 
heart, the cardiomyocyte, is still not understood. Early investigations of our group (Dr. 
Christiane Vettel, Medical Faculty Mannheim, Institute for Experimental and Clinical 
Pharmacology and Toxicology) verified its potential function within this signaling context in 
neonatal rat cardiomyocytes (NRCM). Out of the three GPCR ligands endothelin-1 (ET-1), 
phenylephrine (PE) and angiotensin II (AngII), ET-1 was most effective in RhoA activation and 
was thus used for further examinations (Fig. 1 A). The influence of p63RhoGEF on the ET-1-
dependent RhoA activation was then studied by gain- and loss-of-function experiments. As 
shown in figure 1 B, adenoviral overexpression of p63RhoGEF basally increased RhoA activity 
and further augmented ET-1-induced RhoA activity. Vice versa, the adenovirally mediated 
knockdown of p63RhoGEF reduced the ET-1-induced RhoA activation by about 50%. 
Interestingly, the PE-induced RhoA activation was independent of p63RhoGEF in NRCM 
(Fig. 1 C). 
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Fig. 1: Impact of p63RhoGEF on the ET-1-, PE- and AngII-dependent RhoA activation in NRCM. 
A) Serum-starved NRCM were treated with 100 nM ET-1, 1 µM AngII or 100 µM PE for 30 s and RhoA activation 
was determined by a pulldown assay. The protein content for RhoA-GTP and total RhoA was determined by 
immunoblotting. ET-1 induced activation of RhoA is given by the ratio of the stimulated condition to the unstimulated 
control as mean ± SEM, n=26, *p<0.03 vs. control. B) Serum-starved NRCM were transduced for 48 h with 
recombinant adenoviruses encoding for EGFP only or for full length p63RhoGEF and treated with 100 nM ET-1 for 
30 s. For the determination of RhoA activation, a pulldown assay and immunoblot was performed. For the 
determination of p63RhoGEF expression, an anti-c-myc antibody was used. Representative immunoblots are 
shown. C) Serum-starved NRCM were transduced for 48 h with recombinant adenoviruses encoding for shEGFP 
or for shp63 and treated with 100 nM ET-1 or 100 µM PE for 30 s. A pulldown assay and subsequent immunoblot 
was performed for the determination of RhoA activation. In addition, an immunoblot for total RhoA and p63RhoGEF 
was performed. Changes of p63RhoGEF expression and RhoA activation after treatment with 100 nM ET-1 for 
shp63 relative to shEGFP are given as mean ± SEM, p63RhoGEF expression n=8, *p<0.05, RhoA activation n=3-
4, *p<0.05 vs. control. Experiments were performed by Christiane Vettel, Medical Faculty Mannheim, Institute for 
Experimental and Clinical Pharmacology and Toxicology Mannheim; Vettel, C. Dissertation “Charakterisierung des 
Guaninnukleotid-Austauschfaktors p63RhoGEF als neuen Mediator der Gαq/11-induzierten RhoA-
Aktivierung”2009 
These data indicated that p63RhoGEF could indeed play a role in the neurohumoral signaling 
in diseased cardiomyocytes. This idea was further substantiated by the finding that after 
transverse aortic constriction, which over time leads to heart failure, p63RhoGEF was up-
regulated as shown by quantitative real-time PCR in Fig. 2 [151]. 
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Fig. 2: Expression of p63RhoGEF after transverse aortic constriction (TAC) determined by qPCR. 
Hearts of mice (male and female) which had been subjected to TAC were used for RNA isolation and qPCR analysis 
7 days after the intervention. p63RhoGEF was normalized to the housekeeping gene PBGD. Values are given as 
mean ± SEM relative to sham, n=4 (sham), n=8 (TAC), *p<0.05. 
Moreover, our group (Dr. Anita Ongherth, Institute of Pharmacology and Toxicology, University 
Medical Center Göttingen) demonstrated in a parallel study that in mice with a global 
heterozygous deletion of p63RhoGEF (HET), the cardiac function was impaired already under 
basal conditions but even more detrimental after transverse aortic constriction as shown in 
Fig. 3 A. Surprisingly, surviving mice with a homozygous deletion of p63RhoGEF (KO) showed 
only the same degree of impairment as the corresponding wildtype (WT) littermates (Fig. 3 A). 
However, the mortality after the TAC procedure was much higher in male p63RhoGEF-KO 
mice than in WT or HET mice (Fig. 3 B). 
 
Fig. 3: Impact of genetic deletion of p63RhoGEF for male mice subjected to TAC. 
A) Fractional area shortening (FAS) was determined by echocardiography under basal condition, 1 week, 2 weeks 
and 5 weeks after TAC for wildtype (WT), heterozygous (HET) and homozygous (KO) mice. Values are given as 
mean ± SEM, *p < 0.05 vs. WT basal group, §p < 0.05 vs. HET basal group, ¥p < 0.05 vs. KO basal group, #p < 
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0.05 vs. WT and/or KO group were compared by ANOVA or two conditions by an unpaired t-test. B) Survival rate 
of WT, HET and KO male mice in the first 21 days after the TAC intervention. 
Based on data on p63RhoGEF in NRCM and the heart as described above, and based on the 
fact that RhoA activation has never been studied in adult cardiomyocytes, the following aims 
of this thesis had been defined: 
• Characterization of the GPCR-induced RhoA activation and localization in isolated 
adult mouse cardiomyocytes 
 
• Characterization and determination of the role of p63RhoGEF in adult mouse 
cardiomyocytes by adenoviral overexpression and a genetic deletion approach 
 
• Investigation of the pathophysiological changes and the relevance of p63RhoGEF and 
RhoA signaling in diseased cardiomyocytes 
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3. Materials and Methods 
3.1 Animals 
All animal experiments were performed in accordance with international and governmental 
guidelines. All animal strains used in this thesis are listed below. 
Tab. 1: Animals 
Animals Source 
Wistar Kyoto rat In house breading 
C57BL/6J mice Charles River 
sv129/C57BL/6J inGenious, NY, USA 
3.2 Adenoviruses 
Tab. 2: Adenovirus 
Adenovirus Source 
Ad-EGFP (EGFP sequence) Susanne Lutz, Mannheim 
Ad-p63RhoGEF (c-myc tag, human p63RhoGEF 
sequence aa 1-580, EGFP) 
Susanne Lutz, Mannheim 
Ad-p63ΔN (c-myc tag, human p63RhoGEF 
sequence aa 295-580, EGFP) 
Susanne Lutz, Mannheim 
3.3 Chemicals and media 
Tab. 3: Chemicals and media 
Component Company 
4’,6-Diamidin-2-phenylidol (DAPI) Roche Applied Science, #10236276001 
Acetic acid Carl Roth, #KK62.1 
Acrylamide solution rotiphorese gel 30 Carl Roth, #3029.1 
Albumin Fraction V Sigma-Aldrich, #A3311 
Ammonium persulfate (APS) AppliChem, #141138 
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Angiotensin II, human (AngII) Sigma-Aldrich, #A9525 
Ascorbic acid AppliChem, #A1052 
Bovine serum albumin Sigma-Aldrich, #A2153 
Bromophenol blue Sigma-Aldrich, #B0126 
Calcium chloride (CaCl2) AppliChem, #A1873 
D(+)-Glucose AppliChem, #A0883 
di-Sodium hydrogen phosphate dihydrate Carl Roth, #4984 
Dulbecco’s phosphate buffered saline (10 x) Sigma-Aldrich, #D5652-10X1L 
Endothelin-1 (ET-1) Enzo, #ALX-155-001 
Ethidium bromide Sigma-Aldrich, #E1510 
Fluoromount Sigma-Aldrich, #F4680 
Glycerol AppliChem, #A0970 
Glycine AppliChem, #A3707 
HEPES Carl Roth, #HN77 
Igepal CA-630 Sigma-Aldrich, #I8896 
Magnesium sulfate heptahydrate MgSO4 x 7H2O Merck, #105886 
Methanol Carl Roth, # 0082 
Methyl-β-cyclodextrin (MβCD) Sigma-Aldrich 
Monobasic potassium phosphate (KH2PO4) Carl Roth, #P018 
Paraformaldehyde (PFA) Sigma-Aldrich, P6148 
PBS powder Sigma-Aldrich, #P3813 
Phalloidin, FITC labeled Sigma-Aldrich, #P5282 
Phenol red Sigma-Aldrich, #P0290 
Phenylephrine (PE) Sigma-Aldrich, #P1240000 
Ponceau S Sigma-Aldrich, #P3504 
Potassium bicarbonate (KHCO3) Roth, #P748 
Potassium chloride (KCl) Roth, #HN77 
Precision Plus Protein Kaleidoscope Prestained 
Protein Standards  
Bio-Rad, # 1610375 
ProLong® Gold Antifade Mountant Molecular Probes, Life Tech., #P36934 
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Roti-Block Carl Roth, #A151 
Roti-Immunoblock Carl Roth, #T144 
Rotiphorese Gel 30 Roth, #3029.1 
Sodium bicarbonate (NaHCO3) Carl Roth, #0965 
Sodium chloride (NaCl) Thermo Scientific, #AM9759 
Sodium hydroxide (NaOH) Carl Roth, #K021 
SuperSignal™ West Femto Maximum Sensitvity 
Substrate 
Thermo Scientific, #34095 
Taurin Carl Roth, #4721 
Tetramethylethylenediamine (TEMED) Merck, #110732 
Tris (ultrapure) AppliChem, #A1086 
Triton-X-100 Carl Roth, #3051 
Trypsin 2.5% (10 x) Gibco, #15090-046 
Tween-20 Carl Roth, #9127 
β-Mercaptoethanol AppliChem, #A1108 
3.4 Cell culture 
Tab. 4: Media 
Media Company 
Dulbecco’s Balanced Salt Solution DPBS (-
Ca2+, -Mg2+) 
Gibco, #14190094 
Dulbecco’s Modified Eagle Medium 
DMEM Glutamax (1g/L, pyruvic acid) 
Gibco, #10567014 
Dulbecco’s Modified Eagle Medium DMEM 
(1g/L, NaHCO3) 
Merck Millipore, #F0415 
Fetal calf serum (FCS) Gibco, #10270-106 
Insulin-Transferrin-Selenium-Ethanolamine Gibco, #515500056 
Laminin (1mg/ml) Sigma-Aldrich, #L2020 
L-Glutamine (200 mM) Gibco, #25030024 
Minimal Essential Medium (MEM) Gibco, #51200-046 
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Penicillin/ (1000 U/ml) / 
Streptomycin 10000 µg/ mL) (P/S) 
Gibco, #15140-122 
10 x Phosphate-buffered saline pH 7.4 (Ca2+, -
Mg2+) 
Gibco, 70011-036 
10 x Phosphate-buffered saline (10xPBS), 
pH 7.4 
Thermo Scientific, #70011044 
3.5 Drugs 
Tab. 5: Drugs 
Agent Company 
Burpenophin (Temgestic) Reckitt Benckiser Healthcare 
Fentanyl Rotexmedica 
Isoflurane (Forene) Abbvie, #N01AB06 
Meatmizol (Novaminsulfon) Ratiopharm 
Medetomidine (Ceptor) cp Pharma 
Midazolam Rotexmedica 
3.6 Enzymes and inhibitors 
Tab. 6: Enzymes and inhibitors 
Product name Company 
(-)-Blebbistatin Cayman, #Cay13013 
cOmplete Protease Inhibitor cocktail tablets Roche Applied Science, #04693159001 
Liberase DH Research Grade (100 mg) Roche Applied Science, #05401089001 
Phosphatase Inhibitor Cocktail Tablets Roche Applied Science, #04906837001 
Trypsin 2.5% (10x) Gibco, #15090-046 
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3.7 Kit 
Tab. 7: Kit 
Kit Company 
GoTaq G2 Green Master Mix Promega, #M7822 
RhoA G-Lisa activation assay Cytoskeleton, #BK121 
SuperSignal West femto maximum sensitivity 
substrate 
Thermo Scientific, #34095 
3.8 Consumables 
Tab. 8: Consumables 
Consumables Company 
Cell culture dish (100 x 20 mm) Falcon, #353003 
Cell culture dishes (6,10, 15 cm) Sarstedt/ Graeiner 
Cell scraper Sarstaedt, #83.1830 
Coverslips Ø18 mm Thermo Scientific, Menzel, #CB00180RA1 
Filter System 0.2 µm (1 L, 500 mL, 250 mL) Corning Life Sciences #43051x 
Microscope slide 25 x 75 x 1 mm Thermo Scientific, Menzel #J1800AMNZ 
Multi-well cell culture plates (6-, 12-well) Greiner Bio One 
Nail polish DM drugstore 
Nitrocellulose membrane, 0.2 µm GE Healthcare, #10600001 
Pipette tips filtered (10 µL, 100 µL, 200 µL, 
500 µL) 
Sarstedt 
Reaction tube (15 mL, 50 mL) Greiner Bio One 
Reaction tube (0.5 mL, 1.5 mL, 2 mL) Sarstedt 
Serological pipette wide opening (10 mL) Falcon, #357504 
Serological pipettes (5 mL, 10 mL, 25 mL) Sarstedt, #86.1253.001, #86.1254.001, 
#861685.001 
Syringe filter 0.22µm Sarstedt, #83.1826.001 
Syringe, Omnifix® 40 Solo Braun, #9161309V 
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Transfer pipette Sarstedt, #68.1171 
3.9 Devices 
3.9.1 General devices 
Tab. 9: Devices 
Device Company 
BioSafety Cabinet Prettl, Telstar Bio-II-A 
Cell counter Roche, CASY Counter 
Electronic scale Sartorius, #pt600 
Electronical microscale Sartorius, #AX224 
Electrophoresis chamber Bio-Rad, Mini Protean Tetra Cell 
Heating block Eppendorf, Multimixer compact 
Chemiluminescence imaging system Bio-Rad, #ChemiDoc MP 
Incubator Labotect, C200 
PCR Eppendorf, #Mastercycler gradient 
pH meter Inolab 
Power supply Bio-Rad, Power PAC HD 
Table centrifuge Eppendorf, Centrifuge 5415D 
Vibratom Leica, VT1000S 
Vortexer W.Krannich, VF2 
Western blotting system Bio-Rad, Mini Trans-Blot Cell 
 
3.9.2 Langendorff perfusion system 
Tab. 10: Components of the Langendorff perfusion system 
Device Company 
3-way Stopcock Connection Tubing Braun, #Discofix® C 3-way 
Heat exchanger coil Rettberg 
Peristaltic pump Ismatec, #ISM831C 
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Silicon tubing peristaltic tubing IDEX Health & Science ,#TYGON R3607) 
Stopcock Connection Tubing Braun, # Discofix® C  
Water bath Pharmacia LKB, #Multi TempII 
Cold light source Zeiss, #Schott KL200 
Inverted microscope Nikon, #TMS-F 
Stereo microscope Zeiss, #Stemi 2000 
 
3.9.3 Microscope 
Tab. 11: Microscope 
Microscope Company 
Stereoscope 
Microscope objective 0.8x 
Microscope camera 
Halogen light source 
Fluorescence lamp 
Zeiss, #Lumar.V12 
Zeiss, #NeoLumar S 0.8xFL 
Zeiss, #AxioCam MRc 
Zeiss, #KL2500 LCD 
Zeiss, #HXP120C 
Confocal laser scanning microscope 
Microscope objective 10x 
Microscope objective 20x 
Microscope objective 63x 
Zeiss, LSM 710 
Zeiss, EC Plan-Neofluar 10x/0.3 #440330-9902 
Zeiss, EC Plan-Neofluar 20x/0.5 #440340-9904 
Zeiss, Plan-Apochromat 63x/1.40 NA # 420780-
9900-000 
3.10 Software 
Tab. 12 Software 
Program Provider 
Amon32 FMI VitroDat 
Endnote X7 Thomson Reuters 
Fiji http://fiji.sc/ 
ImageJ 1.51a http://imagej.nih.gov/ij/ 
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Image Lab 5.1 Bio-Rad Laboratories 
MATLAB R2012b MathWorks 
Office 2016 Microsoft Inc. 
Prism 5.0 GraphPad Software 
Xcellence pro Olympus 
Zen 2009 Carl Zeiss 
Zen 2012 Carl Zeiss 
3.11 Cell Culture 
3.11.1 Media and buffers 
Tab. 13: Media and buffers 
Media and buffers Composition 
Stock Perfusion buffer 10 x 
(adjust pH 7.4, with 2N NaOH, sterile filtration, 
storage in a water boiled glass bottle) 
1.13 M NaCL 
47 mM KCl 
6 mM KH2PO4 
6 mM Na2HPO4 x 2 H2O 
12 mM MgSO4 x 7 H2O 
100 mM KHCO3 
100 mM HEPES 
in ddH2O 
 
Perfusion buffer 1 x 23 mM NaHCO3 
30 mM Taurine 
5.5 mM Glucose 
9.9 mM BDM 
10% (v/v) Stock Perfusion buffer 10 x 
ad 500 mL ddH2O 
 
CaCl2-solution 1 100 mM CaCl2 
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sterile filtrated (0.2µm pore size) 
 
CaCl2-solution 2 10 mM CaCl2 
Sterile filtrated (0.2µm pore size) 
 
Liberase solution 0.4% (w/v) Liberase DH  
(bottle contains 50 mg) 
ddH2O.(12 mL) 
 
Digestion buffer 29.6 mL Perfusion buffer 1 x 
3.75 µL Calcium solution 1 
450 µL Liberase solution 
200 µL Trypsin 2.5% 
 
Stopping buffer stock 1% (w/v) BSA 
10 mL Perfusion buffer 1 x 
 
Stopping buffer 1 2.25 mL Stopping buffer 
1.25 µL Calcium solution 1 
 
Stopping buffer 2 4.75 mL Stopping buffer 
1.9 µL Calcium solution 1 
 
Culture medium adult mouse cardiomyocytes 
(AMCM) incubation for 1 hour in 37°C, 5% CO2 
MEM (prewarmed, 37°C,5% CO2) 
0.25% (v/v) (-)-Blebbistatin (0.5 mM) 
1% (w/v) BSA 
1% (v/v) P/S 
1% (v/v) L-Glutamine (200mM) 
1% (v/v) ITS-X 
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Laminin solution 0.01% (w/v) 
in AMCM-medium 
3.12 Antibodies 
3.12.1 Primary antibodies 
Tab. 14: Primary antibodies 
Antibody Company Application Dilution 
Mouse anti-Active RhoA (RhoA-
GTP 
NewEast Biosciences, #26007 IF 1:500 
Rabbit anti-Caveolin-3 Abcam IF 1:500 
Mouse anti-Caveolin-3 BD Biosciences IF 
WB 
1:500 
1:500 
Rabbit anti-Myomesin-1 Proteintech IF 1:500 
Rabbit anti-Connexin-43 Sigma-Aldrich IF 
WB 
1:500 
1:1000 
Rabbit ant-c-myc Santa Cruz IF 1:150 
Mouse anti-c-myc Sigma-Aldrich IF 1:2500 
Rabbit anti-KDEL Abcam, #ab176333 IF 1:100 
Mouse anti-GM-130 BD Biosciences, #610822 IF 1:500 
Mouse anti-RhoA Santa Cruz, #sc-418 WB 1:200 
Mouse anti- α-actinin Sigma-Aldrich, #A7811 IF 
WB 
1:800 
1:2000 
Mouse anti- α-tubulin Sigma-Aldrich WB 1:2000 
Mouse anti-β-actin Sigma-Aldrich, A2228 WB 1:5000 
Rabbit anti-Calsequestrin Thermo-Fisher, PA1-913 WB 1:2000 
Rabbit anti-p63RhoGEF Proteintech, #51006 WB 1:200 
Rabbit anti-GEFT Proteintech, #14839   
Rabbit anti-Dysbindin Sigma-Aldrich, #SAB4200409 IF 1:500 
Rabbit anti-ERM 
(Ezrin/Radixin/Moesin) 
  1:1000 
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Rabbit anti-P-ERM 
(Ezrin/Radixin/Moesin) 
   
3.12.2 Secondary antibodies 
Antibody Company, Application Dilution 
Anti-mouse IgG linked peroxidase-
produced in rabbit 
Sigma-Aldrich, #A9044 WB 1:10000 
Anti-rabbit IgG linked peroxidase 
produced in goat 
Sigma-Aldrich, #9169 WB 1:40000 
AlexFluor®568 goat anti mouse Life Technologies, # A11004 IF 1:1000 
AlexFluor®633 goat anti-rabbit Life Technologies, # A21070 IF 1:1000 
3.13 Solutions for immunostaining 
Tab. 15: Solutions for immunostaining 
Solution Composition 
4% PFA in PBS  
(pH 7.4) 
4% (w/v) paraformaldehyde 
0.01% (v/v) 10 N NaOH 
10% (v/v) 10x PBS 
 
in ddH2O, pH 7.4, HCl 
Permeabilization buffer 0.2% (v/v) Triton-X-100 
in 1 x DPBS (-Ca2+, -Mg2+) 
 
Blocking buffer 
(adult mouse ventricular cardiomyocytes) 
0.2% Triton-X-100 
10% FCS 
in 1 x DPBS (-Ca2+, -Mg2+) 
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3.14 Solution for immunoblotting 
Tab. 16: Solution for immunoblotting 
Solution Components 
10% Ammonium persulfate (APS) 10% (w/v) Ammonium persulfate 
in ddH2O 
 
10% Sodium dodecyl sulfate (SDS) 10% (w/v) Sodium dodecyl sulfate 
in ddH2O 
 
10x Tris buffered saline buffer (10 x TBS) 1.2% (w/v) Tris 
8.8% (w/v) NaCl 
in ddH2O 
 
4x loading buffer 1 (Laemmli buffer) without 
glycerol 
0.2% (w/v) bromophenol blue 
3.6% (w/v) Tris 
5.7% (w/v) SDS 
10% (v/v) β-mercaptoethanol 
in ddH2O 
 
4x loading buffer 2 (+ glycerol) 0.2% (w/v) bromophenol blue 
3.6% (w/v) Tris 
5.7% (w/v) SDS 
50% (v/v) glycerol 
10% (v/v) β-mercaptoethanol 
in ddH2O 
 
5x SDS electrophoresis buffer 0.5% SDS 
1.5% (w/v) Tris 
9.4% (w/v) glycine 
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in ddH2O, pH 8.3 HCl 
 
Blocking buffer 10% (v/v) Roti-Block 
in ddH2O 
 
Blotting buffer 0.3% (w/v) Tris 
1.44% (w/v) glycine 
20% (v/v) methanol 
in ddH2O 
 
cOmplete Protease Inhibitor cocktail (7x) 1 tablet in 1.5 mL in DdH2O 
 
Lysis buffer (GST-Fish buffer) 50 mM Tris 
150 mM NaCl 
4 mM MgCl2 
10% (v/v) glycerol 
1% (v/v) IGEPAL CA-630 
in ddH2O 
 
PhosStop Phosphatase Inhibitor cocktail (10x) 1 tablet in 1 mL in ddH2O 
 
Ponceaus S 0.2% (w/v) Ponceau S 
3% acetic acid 
in ddH2O 
 
Tris buffered saline buffer with tween 20 (TBS-T) 0.1%(v/v) tween 20 
10% (v/v) 10 x TBS 
in ddH2O 
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3.15 Methods 
3.15.1 Mouse disease models 
All animal procedures were reviewed and approved by international animal care and use 
committee at University Center Göttingen and by the veterinarian state authority LAVES 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit) in 
compliance with the human care use of laboratory animals. During this study, two different 
mouse models were investigated. To understand signaling processes during pressure overload 
and the corresponding development of hypertrophy, the transverse aortic constriction model 
was chosen. To specifically investigate the role of the p63RhoGEF, global hetero- and 
homozygous knockout mice were used as model organisms. 
3.15.2 Transverse aortic constriction (TAC) 
TAC surgery was performed by the CRC 1002 service unit, particularly by Sarah Zafar 
(technical assistant). In brief, 9 weeks old male mice (C57BL/6J, Charles River) were used for 
the surgery. As pre-operative pain medication, mice were treated with metamizole (1.33 mg/ml) 
in sugar supplemented drinking water three days before the intervention. Additionally, the 
animals were subcutaneously injected with buprenorphine 1 h before and 24 h after the 
intervention. Mice were anesthetized with an intraperitoneal injection of a mixture containing 
medetomidine (0.5 mg/kg body weight), midazolam (5 mg/kg body weight) and fentanyl (0.05 
mg/kg body weight) diluted in 0.9 % physiological salt solution. This combination was injected 
in a volume of 0.01 mL/g body weight. To antagonize the anesthesia, atipamezole (2.5 mg/kg 
body weight) and flumazenil (0.5mg/kg body weight) were injected subcutaneously after the 
surgery. 
After fixation of the animal with tape, body temperature was kept at 37°C on a heating plate, 
the coat on the chest was removed and the dermis was cleaned. After opening the chest 
upstream to the sternum by a minimal invasive incision the aortic arch was accessible for 
stricture. Therefore, a 27-gauge spacer was placed close to the aorta between the left and the 
right carotid artery and the constriction was performed with a suture (6-0). After proper 
placement of the knot, the spacer was removed, the chest and the skin were closed properly 
with suture (5-0). During recovery phase, the mice were closely monitored. Daily observation, 
documentation of the body weight, and metamizole medication were continued for 7 days. 
Additionally, as control the same number of animals underwent the same intervention with 
exception for the aortic constriction (sham group). The resulting pressure gradient in the 
transverse aorta was confirmed by Doppler echocardiography three days after surgery (refer 
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to chapter 3.15.3). Four weeks after the intervention, cardiomyocytes were isolated from TAC 
and sham mice by Langendorff perfusion (refer to chapter 3.16.1). 
3.15.3 Doppler echocardiography 
To determine the pressure gradient in the transverse aorta after TAC, t pulse wave Doppler 
echocardiography was applied. For that purpose, a 20 Hz transducer (MS250 MicroScan™ 
transducer) was placed close to the constriction and the blood flow velocity (m/s) was 
measured three times per mouse. The measured velocity was converted to a pressure gradient 
(mmHg) using the following calculation: 
Gradient (mmHg) = (mean maximal velocity (m/s))2∙4 
3.15.4 Echocardiography 
One week before and 4 weeks after the TAC or sham intervention, mice were characterized 
by echocardiography. For the measurements, mice were anesthetized with 1-2% (v/v) 
isoflurane in oxygen (1L/min) and the body temperature was kept to 37°C with a heating plate. 
Left ventricular dimensions and wall thicknesses were determined by parasternal long and 
short axis views. The ejection fraction (EF) was calculated as EF = (Vold - Vols) / Vold x 100 
with Vold = heart volume in diastole and Vols = heart volume in systole. Heart volumes were 
calculated as Vold = 5/6 x Aread x Ld and Vols = 5/6 x Areas x Ls with Area denoting the area of 
the endocardium and L denoting the long heart axis in diastole and systole, respectively. 
3.15.5 Transgenic mouse model: p63RhoGEF-knockout 
The founder animals for the p63RhoGEF mouse line in Göttingen were purchase from the 
company Ingenious Targeting Laboratory, Inc. (New York, USA). This mouse line was 
generated with the Cre/loxP system, by adding two flox elements on chromosome 10 
encompassing exon 1 and 2 of the p63RhoGEF gene (Fig. 4). 
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Fig. 4 : Schematic view of the loxP-sites at p63RhoGEFflox and p63RhoGEF- allele 
The scheme visualizes the location of the loxP-sites (red arrows) in the sequence of p63RhoGEF on 
chromosome 10. 
In previous work, heterozygous (p63RhoGEFwt/ko) were generated and backcrossed with wild 
type mice (C57BL/6J, Charles River). Male littermate from the second generation (N2) were 
used for the experiments. 
To investigate the influence of p63RhoGEF in cardiomyocyte signaling, cardiomyocytes were 
isolated from wild type, homozygous and heterozygous knockout male animals at an age 
between 12 and-20 weeks. To study the role of p63RhoGEF during the development of 
hypertrophy, transgenic were compared with wild type mice subjected to transverse aortic 
constriction/intervention (refer to chapter 3.15.2). 
3.15.6 Isolation of the DNA for genotyping 
For genotyping ear or tail biopsies were used. In brief the biopsies were incubated in 50 µL 
alkaline lysis buffer for 1 h at 95°C. Then 50 µL neutralization buffer was added. The obtained 
samples were directly used for PCR reaction. The sequences of the used oligonucleotides, the 
composition of the PCR samples and the design of the PCR program are listed in the tables 
below (Tab. 17, Tab. 18,Tab. 19). 
Tab. 17: Primer for genotyping 
Primer Sequence (5’ to 3’) 
Lox1 (forward) CTG GAA TTG CTG CCA GAC TGT AGC 
Nrev (reverse) ATC CTG AGC ATA GCA CAG ATC TGC GG 
SDL2 (reverse) CCA CCG CAG CCA AAC TTC TC 
  
  34 
Tab. 18: Master mix for PCR 
Components Volume [µL] 
Forward primer (10 pmo) 1 
Reverse primer (10 pmol) 1 
GoTag Green master mix 10 
H2O 20 
Template DNA 1 
 
Tab. 19: PCR cycle program 
Step Time Cycle 
1.Initialization (94°C) 3 min 1x 
2. Denaturation (94°C) 30 sec  
30x 3.Annealing (56°C) 30 sec 
4.Elongation (72°C) 2 min 
5.Elongation (72°C) 5 min 1x 
6.End (4°C) ∞  
 
The obtained PCR products were separated by gel electrophorese using 1.5% agarose gels 
in 1x TAE solution, at 120 V for 45 min. The gels were documented with the GelDoc XR device 
and analyzed with the Quantity One software. The obtained pattern of PCR products of the 
different genotypes is given in the following table (Tab. 20) 
Tab. 20: Genotype specific PCR products 
Genotype Lox1 / SDL2 Lox1 / Nrev 
Wildtype 
(p63RhoGEFflox) 
345 bp no fragment 
Heterozygous 
(p63RhoGEFflox/-) 
345 bp 591 bp 
Knockout 
(p63RhoGEF-/-) 
no fragment 591 bp 
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3.16 Cell culture 
3.16.1 Isolation of adult mouse ventricular cardiomyocytes 
Ventricular myocytes of adult mice were isolated by retrograde Langendorff perfusion using an 
enzyme composition of collagenase type I and II, dispase (Liberase DH, Roche) and trypsin. 
Before each isolation, the Langendorff perfusion system was flushed with 50 mL water and 20 
mL perfusion buffer while preheating the water bath and the tubing system. A petri dish with 
rounded black silicon (self-made) was filled with perfusion buffer on ice in a Styrofoam tray. 
The protocol for the isolation of adult ventricular cardiomyocytes was modified from Borner et 
al. [155].The mice (age of 10 to 20 weeks) were anesthetized with 2% isoflurane in oxygen 
and sacrificed by cervical dislocation. After fixation on a Styrofoam plate and disinfection with 
70% ethanol, the thorax was opened. The heart was isolated by cutting distal from the heart, 
close to the aortic arch and was directly transferred into ice-cold perfusion buffer. For perfusion, 
the aorta was cannulated with a buffer-filled modified 20G cannula. The heart was connected 
to the pre-heated (37°C) perfusion system with a flow of 3.5 mL per min and washed for 30 
sec. Afterwards, 29.6 mL digestion buffer was added to the system. During the digestion of the 
heart, 2.5 mL of digestion buffer was collected in a beaker. After perfusion with 29.6 mL of 
digestion buffer, the ventricles were separated from the atria, placed into the beaker and further 
dissected into 1-2 mm3 pieces. To stop the digestion, 2.5 mL stopping buffer 1 was added and 
the cardiomyocytes were further homogenized with a wide opening syringe (Braun Omnifix). 
Undigested tissue was sedimented and removed, while the digested cell suspension was 
transferred to a 15 mL reaction tube. After sedimentation of the cell suspension (8 min), the 
supernatant was discarded and the pellet was resuspended in 4.75 mL stopping buffer 2. The 
recalcification was performed by adding the listed volumes of calcium solutions and 
resuspension with a wide opening serological pipette allowing 4 min adaptation time between 
every single step. 
Tab. 21: Recalcification steps 
Volume Calcium stock Final concentration 
25 µL CaCl2 10 mM 62 µM CaCl2 
25 µL CaCl2 10 mM 114 µM CaCl2 
50 µL CaCl2 10 mM 191 µM CaCl2 
20 µL CaCl2 100 mM 498 µM CaCl2 
30 µL CaCl2 100 mM 960 µM CaCl2 
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After recalcification, the cell suspension was allowed to sediment by gravity until the distinct 
formation of a cell pellet occurred, which was then resuspended in fresh pre-warmed adult 
mouse cardiomyocyte (AMCM) medium. Afterwards, the cardiomyocytes were plated as 
droplets on laminin-coated glass cover slips (Ø 18mm) in a 12-well plate or seeded in uncoated 
6-well plates. The cells were incubated for 30 min at 37°C and 5% CO2. Unattached cells were 
removed, and AMCM medium was added. The attached cardiomyocytes were cultured for 24 
to 48 h at 37°C and 5% CO2. 
3.16.2 Depletion of cholesterol from the membrane of cardiomyocytes 
Cholesterol was depleted by adding methyl-β-cyclodextrin (MβCD) to the culture medium of 
adult cardiomyocytes. For treatment, the culture medium was discarded and methyl-β-
cyclodextrin containing medium with the concentrations listed in the table below (Tab. 22: 
Concentration methyl- β -cyclodextrin) was added to the cells. 
Tab. 22: Concentration methyl- β -cyclodextrin 
Cell type Concentration 
Adult mouse cardiomyocytes 0.3 mM 
Adult mouse cardiomyocytes were treated directly after isolation and attachment by adding 
MβCD to the culture medium. The cardiomyocytes were cultured for 24 h in MβCD containing 
medium before they were used for further analyses. 
3.16.3 Adenovirus transduction 
Adult mouse cardiomyocytes were seeded as described before (refer to 3.16.1) and during the 
exchange of the culture medium after plating, adenovirus containing AMCM medium was 
added to the cells. The AMCMs were incubated for 36 - 48 h with a MOI of around 100-500. 
During the transduction, the culture was screened for GFP-positive cells via fluorescence 
microscopy. In addition, morphology, contractile behavior and viability of the cells were 
observed. 
3.16.4 GPCR stimulation of adult mouse cardiomyocytes 
In order to compare RhoA activation through stimulation of various G protein-coupled 
receptors, freshly isolated adult mouse ventricular cardiomyocytes were isolated from the three 
genotypes p63RhoGEFwt/wt, p63RhoGEFko/ko and p63RhoGEFwt/ko as described in chapter 
3.16.1 at the same day. Alternatively, AMCM were isolated from untreated C57BL/6J mice or 
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after sham and TAC intervention. To reduce the influence of isolation-dependent effects on the 
RhoA activation, the cells were cultured for 24 h in AMCM medium at 37°C, 5% CO2. 
After 24 h of culture, the medium was discarded and 500 µL pre-warmed AMCM medium with 
the diluted receptor agonists, which are listed below, were added for 90 sec. Afterwards the 
cells were immediately fixed with 4% PFA as described in chapter 3.17. 
Tab. 23: Stimulants and the corresponding concentrations for treatment of AMCM 
Stimulant Final concentration 
Endotheline-1 50 nM 
Angiotensin-II 100 nM 
Phenylephrine 100 µM 
3.17 Fixation and staining of cardiomyocytes for immunofluorescence 
Adult mouse cardiomyocytes were fixed in 4% PFA in 1x DPBS either directly after seeding, 
after 24 h when treated or after 48 h when adenovirally transduced. For fixation, the respective 
medium was discarded and 500 µL 4% PFA in PBS (pH 7.4) were added for 6 min. After 
washing the cells twice with 1x DPBS, the cells were permeabilized and blocked with 500 µL 
blocking buffer 2 for 1 h. Adult cardiomyocytes all antibodies were diluted in blocking buffer 2, 
which contained FCS instead of Immunoblock. The incubation time with DAPI and FITC-
phalloidin was reduced to 30 min. All further steps were performed as described above. Finally, 
cells were washed 3 times for 10 min with 1x DPBS at RT and mounted with a droplet of 
ProLong gold antifade mountant and stored light protected for 48 h. To stabilize the mounted 
samples, the cover slips were sealed with transparent nail polish. 
3.18 Confocal microscopy 
Confocal microscopy was used to image immunostained and fixed adult mouse 
cardiomyocytes. Imaging was performed with a confocal laser scanning microscope (LSM 710, 
Carl Zeiss, Jena). The objectives used for imaging are listed below. 
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Tab. 24: Objectives 
Objective Magnification 
EC Plan-Neofluar 10x / 0.3 NA 
EC Plan-Neofluar 20x / 0.5 NA 
Plan-Apochromat 63x / 1.4 NA oil 
To ensure the reproducibility of the imaging process, the proposed stepwise start of the system, 
including holding time, was strictly adhered to. Images were recorded using the software 
ZEN2009 provided by Zeiss and saved as “.lsm” files. For further analysis, images were 
processed using the “.tiff” file converted from the original “.lsm” file with the open access image 
processing software “Fiji” [ImageJ]. 
3.18.1 Confocal imaging and quantification of RhoA-GTP in AMCM 
For detection of RhoA-GTP a primary anti-RhoA-GTP antibody, a secondary antibody coupled 
to AlexaFluor 568 (please also refer to 2.12) and objectives with 63x and 10x magnification 
were used. The 63x Plan-Apochromat oil objective was used for single cell imaging, the 10x 
EC Plan-Neofluar objective for overviews. AlexaFluor 568 was excited at a wavelength of 561 
nm at 2-3% laser intensity. The detection range was set to 572-629 nm. The pinhole opening 
of 1 Airy unit resulted in an optical slice thickness of 800 nm. The detection gain was set to 
500-700. The pixel size for imaging was set to 100 nm x 100 nm. For overviews the dye was 
excited with 5% of the 561 nm laser. The pinhole opening was set to 1 Airy unit which resulted 
in an optical thickness of 30 µm. All cells from one isolation were measured in the same 
imaging session. For that purpose, the determination of imaging settings depended on the 
samples with the highest intensities. 
To determine the RhoA-GTP signal intensities, the open access image analysis software “Fiji” 
[imageJ 1.59] was used. All confocal single cell images of one imaging session were combined 
in one image stack. The cross-sectional area of each cell was selected using the “wand tool” 
with tolerance of 75 with the “legacy” mode and added to the “region of interest (ROI)” 
manager. To exclude signals from the sarcolemma, the selected ROI was reduced by 10 pixel 
with “enlarge selection”-10 pixels and added to the ROI manager. All selections of one stack 
were saved as “date of experiment_genotype_treatment”.zip file. Using the “measurement” 
tool, area and raw integrated density were measured for all ROIs. The resulting data file was 
saved as “date of experiment_genotype_treatment-results”.txt-file. Additionally, the 
fluorescence changes of the overview images were measured as described above using the 
“wand tool” and tolerance of 50-75. For that purpose, the images were combined as a stack. 
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The selection was added to the ROI manager and the area and the raw integrated density was 
measured. The selection and measurements were saved for further methods as described 
above. Thereby the cross-sectional area and the intensities were measured. 
The measured intensities saved in the txt format were imported into Excel and used for 
calculation of the differences in active RhoA intensities at the sarcolemma, the cytosol and the 
overall intensity. Therefore, the sum of the intensities in the selection was divided by the area 
of the selection. By this method the intensities of the whole cell, at the sarcolemma and in the 
cytosol, were quantified. 
3.18.2 Confocal imaging and analysis of immunostained samples  
The imaging settings for each staining were adjusted at the beginning of each imaging session 
and were saved as reusable settings. The different imaging parameters for each dye are listed 
in the table below. Multi-color immunostains were imaged using a combination of the 
corresponding parameters in a frame sequential setting. If not stated differently, immunostains 
were imaged with a 63x Plan-Apochromat oil objective and a pixel size of 100 nm x 100 nm. 
Tab. 25: Microscope settings for different excitation wavelength 
Dye 
Excitation 
wavelength  
Laser power Detection range 
Optical slice 
thickness 
DAPI 405 nm 1% - 2% 410 nm - 482 nm 500 nm 
AlexaFluor 488 488 nm 2% 494 nm - 572 nm 600 nm 
EGFP 488 nm 2% 494 nm - 572 nm 600 nm 
AlexaFluor 568 561 nm 2% - 4% 563 nm - 600 nm 800 nm 
AlexaFluor 633 633 nm 2% - 4% 638 nm - 747 nm 900 nm 
To analyze the striation patterns of the proteins of interest, the “line”- tool was used. For that 
purpose, the line width was set to 20 pixel and a length of 10-12 µm was chosen. The line was 
placed in a 90° angle to the striation pattern (sarcomere), measured and visualized with the 
“plot profile” tool. The plot values were listed and saved as txt-file and further analyzed with 
Excel. Alternatively, the TTorg plugin of ImageJ was used [156]. SSPD was set to 27, the 
minimum spacing to 0.7 µm and the maximum spacing to 2 µm.  
The localization of proteins in the sarcolemma and in the perinuclear region were measured 
with ImageJ. If possible the cells and nuclei were encircled with the wand tool or otherwise by 
hand. For analysis of the density at the sarcolemma, the cell ROI was reduced by 2 µm and 
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the total cell fluorescence as well as the residual cell fluorescence determined. The difference 
between both values reflects the fluorescence in the sarcolemmal region. For the perinuclear 
region the nucleus ROI was enlarged by 2.5 µm. The difference between the enlarged ROI 
and the nucleus ROI reflects the fluorescence in the perinuclear region. In most cases is the 
distribution of a protein given relative to the total detected signal in percent, in order to 
normalize for signal variations between different cells. 
Co-localization analysis of proteins were performed with the Coloc2 plugin of ImageJ. 
Threshold regression was done with the help of the Costes algorithm. Thresholded Manders’ 
correlation coefficients and the Pearson correlation coefficient were used for analysis.  
To analyze the Golgi apparatus in AMCM the following steps were processed for every set of 
isolation. All staining from the same set were imaged as one set to guarantee the same 
microscope and laser condition. First, the channel with the Golgi apparatus images were 
duplicated, all images were combined to a single stack and saved as “tiff” file. Next, the images 
were processed by “subtract background” with a rolling ball radius of 5.0 pixels. The option 
“adjust-threshold” with a value 15-25 was used and the images were analyzed with “analyze 
particles”. The pixel size was set to 2-infinity and “Outlines” were shown. The obtained data 
including particle count, size of particles and cross-sectional area of the cells were saved as 
txt-file. 
Further analysis was performed with Excel and Prism. 
3.18.3 Cell lysate preparation 
Proteins were either isolated from freshly isolated or cultured AMCM. The freshly isolated or in 
liquid nitrogen deep-frozen cardiomyocytes from transgenic, TAC and sham operated mice 
were lysed by adding an adequate volume (100-300 µL) of lysis buffer to the cell pellet. After 
homogenization by pipetting and vortexing, the cell lysates were centrifuged for 10 min at 
12000 x g and 4°C. The soluble protein fraction was transferred into a cold reaction tube and 
4x loading buffer 1 was added. The pellet containing the insoluble protein fraction was directly 
dissolved in 1x loading buffer 2. All samples were denatured at 95°C for 5 min and stored at -
20°C. Protein samples from cultured neonatal cardiomyocytes were prepared on ice by adding 
200-300 µL GST-Fish buffer in each well of a 6-well plate. The lysed cells were collected with 
the help of a cell scraper and transferred into a 1.5 mL reaction tube. Homogenization was 
carried out by repetitive pipetting on ice. For storage, the samples were snap-frozen in liquid 
nitrogen or 4x loading buffer was added and the samples were heated 5 min at 95°C. After 
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cooling, samples were centrifuged and stored until usage at -20°C for short time period or at -
80°C for long term storage. 
3.18.4 Immunoblot analysis 
Proteins were separated by discontinuous sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis using 5% collecting and 8% to 15% separating polyacrylamide gels. The gel 
compositions are listed in the table (Tab. 26: SDS polyacrylamide gel composition. 
Tab. 26: SDS polyacrylamide gel composition 
Gel Composition 
5% SDS-polyacrylamide gel 10 mL ddH2O 
1.7 mL 30% acrylamide rotiphorese gel solution 
1.25 mL 1 M Tris (pH 6.8, HCL) 
0.1 mL 10% SDS 
0.1 mL 10%APS 
10 µL TEMED 
8% SDS-polyacrylamide gel 11.5 mL ddH2O 
6,75 mL 30% acrylamide rotiphorese gel 
solution 
6.25 mL 1.5 M Tris (pH 6.8, HCL) 
0.25 mL 10% SDS 
0.25 mL 10%APS 
15 µL TEMED 
15% SDS-polyacrylamide gel 5.75 mL ddH2O 
12.5 mL 30% acrylamide rotiphorese gel 
solution 
6.25 mL 1.5 M Tris (pH 6.8, HCL) 
0.25 mL 10% SDS 
0.25 mL 10%APS 
10 µL TEMED 
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3.19 Statistics 
All data are presented as mean ± standard error of the mean (SEM). Statistical significance 
was analyzed by unpaired T-test for two group comparison and one-way or two-way ANOVA 
followed by Bonferroni’s post-hoc comparison for comparison of three or more groups 
(GraphPad, Prism 7.0). P-values less than 0.05 were classified as statistically significant. 
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4. Results 
4.1 Analysis of RhoA activation and localization in adult mouse cardiomyocytes 
RhoA expression and activation had been mainly investigated in neonatal rat cardiomyocytes. 
However, in adult cardiomyocytes its expression, activation and localization are unknown. 
Therefore, adult cardiomyocytes were isolated from mouse hearts and confocal imaging of 
immunostainings of inactive and active RhoA was carried out. Active RhoA was detected with 
an antibody recognizing the conformation of GTP-bound, but not GDP-bound RhoA. Confocal 
imaging was performed from central regions of cardiomyocytes and at their surfaces (imaging 
planes are illustrated in Fig. 5 A). Representative images of RhoA-GTP and total RhoA are 
shown in Fig. 5 B. Active RhoA localization appears as a strong signal mainly at the 
sarcolemma and in thin transversally striated lines extending into the cell but not crossing the 
complete cell width. For total RhoA, a transversally striated pattern crossing the complete cell 
width could be observed indicating a sarcomeric localization. However, the total RhoA staining 
did not show a signal at the sarcolemma as compared to the active RhoA staining. 
Furthermore, co-stainings of RhoA-GTP with actin support its localization at the sarcomeric 
Z-line because RhoA-GTP striations show an overlay with actin signals. Co-staining of 
RhoA-GTP with myomesin-1 showed no intracellular overlap in the M-line region (Fig. 5 C). In 
addition to these results, a shift of the imaging plane towards the cardiomyocyte surface and 
co-stainings with actin, myomesin-1, dystrophin and caveolin-3 supported the sarcolemmal 
and sarcomeric localization of RhoA-GTP. At the cardiomyocyte surface, active RhoA co-
localizes with actin filaments but not with myomesin-1 and dystrophin (Fig. 5 D). Caveolin-3 
and active RhoA showed different localization patterns but seemed to minimally overlap in the 
costameric region. Interestingly, a 3D reconstruction of a z-stack imaging experiment 
additionally indicates that active RhoA can be found at intercalated discs of AMCM (Fig. 5 E). 
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Fig. 5: Co-immunostaining of RhoA-GTP with sarcomeric and sarcolemma-associated proteins 
in WT-AMCM 
Adult mouse cardiomyocytes (AMCM) were isolated by modified Langendorff perfusion and cultured on laminin-
coated coverslips for 24 h at 37°C, 5% CO2. A) Schematic illustration of the two different imaging planes center view 
(left) and surface view (right) is shown. B) Representative confocal center view images showing RhoA-GTP (green), 
total RhoA (red) and an overlay of both channels of WT-AMCM. Scale bar 25 µm. C) Representative confocal center 
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view images of co-immunostaining in a WT-AMCM are presented. Shown are the bright field image, RhoA-GTP 
(green), myomesin-1 (red), F-actin (grayscale) in different composites and as merge. Scale bar 25 µm. D) 
Magnification of confocal surface view images of Rho-GTP (green) with F-actin, myomesin-1, dystrophin or 
caveolin-3 (red) of WT-AMCM is shown. Scale bar 10 µm. E) 3D-reconstruction of confocal images (z-stack, 15 
images, total depth 6.5 µm) was generated showing Rho-GTP (green) and F-actin (grayscale) co-staining of two 
WT-AMCM at the intercalated disc. Scale bar 25 µm. 
To further investigate the co-localization of active RhoA and caveolin-3, a colocalization 
analysis was performed with the help of the ImageJ plugin Coloc2. The obtained Pearson's 
correlation coefficient suggested that the co-localization between active RhoA and caveolin-3 
is in general low. However, the Manders' overlap coefficient M2, which reflects the correlation 
of caveolin-3 with active RhoA demonstrated that at least part of caveolin-3 possessed a similar 
localization as active RhoA, whereas only a minor proportion of active RhoA was found in close 
proximity to caveolin-3 demonstrated by the M1 coefficient (Fig. 6). 
 
Fig. 6: Co-immunostaining of RhoA-GTP with caveolin-3 
Adult mouse cardiomyocytes (AMCM) were isolated by modified Langendorff perfusion and cultured on laminin-
coated coverslips for 24 h at 37°C, 5% CO2. Immunofluorescence analysis of active RhoA and caveolin-3 was 
performed. Magnification of representative confocal surface view images of Rho-GTP (green) and caveolin-3 (red) 
of WT-AMCM are shown. Scale bar 10 µm. The colocalization of active RhoA and caveolin-3 was analyzed with the 
help of ImageJ’s plugin Coloc2. M1 reflects the co-localization of active RhoA with caveolin-3 and M2 of caveolin-3 
with active RhoA. Given are the means ± SEM, n=3, 14 cells, *p<0.05. 
Since most of the following experiments have been performed after cultivation of AMCM, it had 
to be excluded that cultivation influences the localization of RhoA and other proteins of interest. 
Therefore, the influence of 24 h compared to 1 h of cultivation on basal RhoA activity was 
analyzed next. By vertical line scans the amount of active RhoA was quantified (Fig. 7 A). Both, 
in freshly isolated AMCM and in AMCM cultured for 24 h, the strongest signal for active RhoA 
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was found at the sarcolemma as described above. Line scan analysis revealed that 24 h of 
cultivation led to a significant increase in active RhoA signal intensity and to a broadening of 
the signal at the sarcolemma indicating an increase of RhoA activity at the sarcolemma 
(Fig. 7 B). In summery the averaged signal intensity showed an increase of the signal width at 
the 50% peak RFU from 0.57 µm to 0.79 µm. This corresponds to a broadening of the RhoA 
signal intensity at the sarcolemma of 0.22 µm and an increased maximum signal intensity by 
59% from averaged peak values of 82.44 RFU to 130.8 RFU. 
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Fig. 7: Quantification of RhoA-GTP intensities at the sarcolemma in 1 h and 24 h cultured WT-
AMCM. 
A) Illustration of the vertical line scan measurement to quantify the relative fluorescence units (RFU) of RhoA-GTP 
at the sarcolemma in a confocal center view image. As depicted by the six bars, six independent regions were 
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measured per cell. Scale bar 25 µm. Graphical description of the measurement per cell. The left graph shows the 
six individual line scans obtained from one cell. Those individual line scans were averaged as shown on the right. 
Data are presented as means ± SEM of one cell. B) AMCM were isolated and cultured on laminin-coated coverslips 
for 1 h or 24 h at 37°C, 5% CO2. Comparison of representative center view confocal images showing bright field 
images, RhoA-GTP (green), F-actin (grayscale) and DAPI (blue) of WT-AMCM cultured for 1 h (left) or for 24 h 
(right) is presented together with the quantification of RhoA-GTP. Data are presented as mean RFU ± SEM, n=3 
cell preparations, in total 15 cells cultured for 1 h, 20 cells cultured for 24 h; 6 line scans per cell, *p<0.05 tested by 
2-way ANOVA. Scale bars 25 µm. 
 
In neonatal rat cardiomyocytes it had been demonstrated that RhoA can be activated by 
G protein-coupled receptors belonging to the Gq/11 and G12/13-coupled families. In order to study 
the activation of RhoA in AMCM, the cells were cultured for 24 h and then treated with 100 µM 
phenylephrine and 50 nM endothelin-1 (PE/ET-1) for 90 sec. For control, cells were treated 
with BSA after 24 h of cultivation. After fixation, confocal imaging of RhoA-GTP and actin was 
performed. Signals were imaged in different imaging planes, coming from the center to the 
surface, and line scans in parallel to the main cell axis were analyzed (Fig. 8 A). 
For active RhoA, changes in signal intensities and frequencies were observed after stimulation 
with PE/ET-1. Those changes were most prominent at the cell surface (Fig. 8 B). Overlays of 
the line profiles of actin and RhoA-GTP showed especially increased signal intensities for RhoA 
in the costamere region at the sarcolemma. Overall, the striated pattern of the active RhoA 
distribution became more pronounced. Periodicity of RhoA-GTP signals was analyzed in the 
different treatment groups at the cell center and at its surface (Fig. 8 B, C). The regular extra 
RhoA-GTP peak at the cell surface led to a decrease of peak-to-peak distances from ~1.8 µm 
(center) to ~0.9 µm. To exclude cell contraction as a source for the observed changes after 
PE/ET-1-treatment, vertical line scan analyses of actin and myomesin-1 were performed. Both 
showed a regular pattern and the peak-to-peak distances of actin was ~1.8 µm under treated 
and control conditions (Fig. 8 D). This result indicates that the described changes in active 
RhoA intensity and distribution was not based on PE/ET-1-induced cell contraction. 
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Fig. 8: Analysis of RhoA-GTP localization and intensity in WT-AMCM after treatment with 
PE/ET-1. 
Adult mouse cardiomyocytes (AMCM) were cultured for 24 h and treated either with BSA or with 100 µM 
phenylephrine and 50 nM endothelin-1 (PE/ET-1) for 90 sec. A) Magnification of a confocal center view image 
showing RhoA-GTP is presented (left). The vertical line (yellow) illustrates where RhoA-GTP localization was 
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analyzed (left). The profile of RhoA-GTP intensities in different imaging depths in a z-stack (every third of 15 images, 
total depth 6.5 µm) were analyzed (right). The graph depicts scan lines from center (light green) to the surface 
(black) of an AMCM treated with PE/ET-1. B) Representative magnifications of confocal images of AMCM stained 
for RhoA-GTP and F-actin at the surface (top) and center (bottom) with the corresponding line profiles is shown. 
Scale bar 10 µm. C) Combination of the different RhoA-GTP line profiles from (B) illustrating the changes in pattern 
in different views for PE/ET-1-treated and BSA condition (left) is presented. Extraction and quantification of the 
peak-to-peak distances from RhoA-GTP line profiles was performed (right). Given are the values of one treatment 
experiment. D) Representative confocal center view images (top) of AMCM cultured for 24 h, treated with BSA (left) 
or PE/ET-1 (right) and stained for myomesin-1 (red) and F-actin (grayscale) are shown. Representative line profiles 
(middle) of F-actin and myomesin-1 are shown. Magnification of F-actin staining demonstrating the sarcomere 
pattern (bottom left) is shown. Representative quantification (bottom right) of the Z-disc peak-to-peak distance in 
control and treated AMCM of one treatment experiment is given. Scale bar 25 µm. 
To confirm the PE/ET-1-induced activation of RhoA in isolated AMCM detected by 
immunofluorescence analysis, a G-Lisa assay was performed. This biochemical assay uses a 
pre-coated surface, which selectively binds the active forms of RhoA, RhoB or RhoC present 
in cell lysates, and a specific RhoA antibody to detect bound RhoA. For normalization an 
immunoblot of the lysates was performed in addition to quantify total RhoA levels. Comparable 
to the immunofluorescence analysis, the G-Lisa experiment demonstrated that RhoA activity 
was significantly increased in AMCM after PE/ET-1 treatment (Fig. 9 A). 
Further analysis of the obtained cell lysates and of the residual insoluble fraction by 
immunoblot revealed that most of the RhoA protein resides in the insoluble fraction. This 
fraction contains in addition sarcomeric proteins as demonstrated by α-actinin (Fig. 9 B). This 
finding supports the above described localization of total RhoA indicating that most of the 
protein is associated to the sarcomere and only the minor fraction of active RhoA resides at 
the sarcolemma.  
To further confirm, that the treatment of AMCM with PE/ET-1 induced the activation of 
heterotrimeric Gq/11 protein signaling, the phosphorylation of the PKC substrates Ezrin/ Radixin/ 
Moesin (ERM) and of ERK1/2 after PE/ET-1 treatment was studied by immunoblotting 
(Fig. 9 C and 9 D). The ratio of phosphorylated ERM to total ERM significantly increased ~3-
fold after treatment. The ratio of phosphorylated ERK1/2 to total ERK1/2 significantly increased 
~2-fold after PE/ET-1 treatment. 
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Fig. 9: Quantification of PE/ET-1-induced changes in RhoA, ERM and ERK1/2 activity in WT-
AMCM. 
Adult mouse cardiomyocytes (AMCM) were isolated and cultured for 24 h. Treatment with 100 µM phenylephrine 
and 50 nM endothelin-1 (PE/ET-1) was performed for 90 sec. A) RhoA-GTP was measured in lysates by G-Lisa 
activity assay kit. Total RhoA was determined by immunoblot in G-Lisa lysates. Given is the ratio of RhoA-GTP and 
total RhoA relative to control. Data are presented as means ± SEM. n=4 control, n=6 treated, *p<0.05 vs. control 
assessed by unpaired t-test. B) Treated and untreated AMCM were lysed with G-Lisa lysis buffer and separated 
into soluble and insoluble fractions by centrifugation. Ponceau-S staining (top) of representative immunoblots 
(bottom) of α-actinin, calsequestrin and RhoA is shown. Representative immunoblots of C) phosphorylated ERM 
and total ERM (left), D) phosphorylated ERK and total ERK (right) in control and PE/ET-1 treated AMCM are shown. 
For quantification (bottom), the signals of the phosphorylated proteins were normalized to the respective total 
protein signals. Data are presented as means ± SEM relative to controls. n=3, *p<0.05 vs. control assessed by 
unpaired t-test. 
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So far, both GPCR agonists ET-1 and PE had been used as a combined treatment for the 
AMCM. For discrimination of their individual effects on the localization of active RhoA, the cells 
were individually treated and the active RhoA pattern was analyzed at the cell surface with the 
help of the ImageJ plugin TTorg [156]. Both ligands induced a more pronounced striated 
pattern on the cell surface of the AMCM compared to control (Fig. 10 A). The analysis 
demonstrated that the fraction of cells having the dominant localization of active RhoA in the 
costamere region (pattern 1.8 µm) increased after application of ET-1 and PE (Fig. 10 B). 
Moreover, the power of the general periodic pattern (0.9 µm) increased after ET-1 and PE 
treatment and of the dominant 1.8 µm pattern after ET-1 application (Fig. 10 C). 
 
Fig. 10: Analysis of RhoA-GTP localization in WT-AMCM after individual treatment with PE and 
ET-1. 
Adult mouse cardiomyocytes (AMCM) were cultured for 24 h and treated either with BSA, with 50 nM endothelin-1 
(ET-1) or with 100 µM phenylephrine (PE) for 90 sec. Immunofluorescence analysis of active RhoA was performed. 
A) Magnification of confocal surface view images showing RhoA-GTP are presented. Scale bar 10 µm B) A pattern 
analysis with the help of the ImageJ plugin TTorg was performed. The fractions of cells showing no pattern, a 
dominant pattern with a striation regularity of around 0.9 µm or 1.8 µm are presented. C) The power of the vertical 
0.9 µm (left) and 1.8 µm (right) pattern is given. In total 20 to 30 cells were analyzed from 3 independent 
experiments. 
Taken together, active RhoA mainly resides in the sarcolemma of adult cardiomyocytes. The 
fraction of active RhoA compared to total RhoA, which showed a preferential sarcomeric 
localization, can be considered as rather low based on the immunofluorescence analysis and 
the biochemical fractionation. In response to the GPCR ligands ET-1 and PE active RhoA 
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increases and translocates to the sarcolemma towards the costameric region as demonstrated 
by actin co-staining. 
4.2 Analysis of RhoA activation and localization in adult mouse cardiomyocytes 
after transverse aortic constriction 
RhoA has been shown to be fast and permanently activated in mouse hearts after TAC [114]. 
However, whether this includes its activation in cardiomyocytes was not demonstrated. 
Moreover, it is not clear how RhoA is activated in the diseased heart. Therefore, transverse 
aortic constriction experiments with C57BL/6J mice were performed (Fig. 11 A). For the control 
group, a sham surgery was performed. Sham mice underwent the same surgical procedure, 
only without the final constriction of the aorta. Three days after the interventions, pressure 
gradients in the aorta were determined by Doppler echocardiography. Compared to control 
mice (sham) with an average gradient of ~8 mmHg, TAC mice had an average pressure 
gradient of ~70 mmHg (Fig. 11 B). In addition, an echocardiographic phenotyping was 
performed before and 4 weeks after the intervention. Four weeks after TAC, the development 
of hypertrophy was observed reflected by a significant increase of the left ventricular weight to 
body weight ratio (LVW/BW) from 4 mg/g to 8 mg/g in the TAC. No changes were found in the 
sham group (Fig. 11 C). Furthermore, the ejection fraction (EF) was significantly reduced from 
~50% to ~30% after TAC (Fig. 11 D) and a significant dilation of the left ventricle had taken 
place as demonstrated by an increase of the diastolic volume from 100 µL to 150 µL (Fig. 11 E). 
Taken together, the transition of compensatory heart hypertrophy to heart failure had taken 
place 4 weeks after TAC. 
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Fig. 11: Analysis of the heart function in response to transverse aortic constriction. 
Nine week old male mice subjected to transverse aortic constriction (TAC) or sham intervention were characterized 
by echocardiography before and 4 weeks after the intervention. A) Schematic illustration of a TAC intervention 
modified from Luo et al., 2015 is presented [157]. B) Pressure gradients in the transverse aorta were measured by 
Doppler echocardiography. Values are shown as means ± SEM, n=5 Sham, n=7 TAC, *p<0.05 assessed by 
unpaired t-test. C) The left ventricular weight to body weight ratio (LVW/BW), D) ejection fraction (EF) and E) 
diastolic volume (Vd) were determined by echocardiography. Values are shown as means ± SEM, n=5 Sham, n=7 
TAC, *p<0.05 assessed by 1 way ANOVA. 
Subsequently, the morphology of isolated cardiomyocytes in cell culture was analyzed. For 
that purpose, ventricular myocytes from TAC and sham mice were isolated and either directly 
fixed or cultured for 24 h before fixation. The isolated and fixed cells were stained for F-actin 
and imaging was performed with a low magnification (10x) to obtain representative overview 
images (Fig. 12). In those overview images, mean cell area, depth, length and width were 
determined. Determination of the cell area revealed a significant increase in TAC-AMCM 
compared to sham-AMCM from 2800 µm2 to 3800 µm2 directly after the isolation. This change 
was slightly reduced to 2500 µm2 in control and 3000 µm2 in TAC-AMCM after 24 h in culture. 
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Consistent with these results, significant increases in mean cell depth, length and width were 
detected for directly fixed and 24 h cultured cells 4 weeks after TAC. As observed for the cell 
area, also cell depth and length were slightly smaller after 24 h in culture compared to directly 
fixed cells. In contrast to these findings, the cells showed a significant increase in cell width 
after 24 h in culture. In summary, it could be shown that the hypertrophic phenotype of isolated 
cardiomyocytes after TAC was preserved during the first 24 h in culture. 
 
Fig. 12: Quantification of morphological changes of AMCM after transverse aortic constriction. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC) intervention and seeded on laminin-coated coverslips. The cells were either directly fixed after 
1 h (direct) or cultured for further 24 h. F-actin was stained with FITC-labeled phalloidin. Representative overview 
images (10x magnification) of directly fixed sham (left) and TAC (right) AMCM are shown. Analyses of AMCM areas 
(middle, top row), cell depths (left, bottom row), cell lengths (middle, bottom row) and cell widths (right, bottom row) 
after direct fixation or 24 h culture are depicted. Values are presented as means ± SEM, n=5 Control, n=7 TAC, 
*p<0.05 assessed by 1 way ANOVA. 
In addition to the analysis of the cell morphology, sarcomere lengths were measured in the 
sham- and TAC-AMCM. After fixation and permeabilization cells were stained with FITC-
labeled phalloidin and DAPI to visualize the sarcomeric Z-lines and the nuclei. After single cell 
confocal imaging, sarcomeric lengths were measured in line scans by peak-to-peak analysis 
of the actin signals. Isolated cardiomyocytes from all groups (directly fixed, cultured for 24 h, 
sham and TAC) showed consistent sarcomere lengths of ~1.8 µm. These results indicate that 
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neither the TAC intervention nor fixation or cultivation had an influence on sarcomere length 
and did not lead to abnormal cellular contraction (Fig. 13). 
 
Fig. 13: Analysis of sarcomere length in AMCM after transverse aortic constriction. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC) and seeded on laminin-coated coverslips. The cells were either directly fixed after 1 h (direct) or 
cultured for further 24 h. F-actin was stained with FITC-labeled phalloidin and nuclei with DAPI. Representative 
confocal center view images of F-actin (grayscale) and nuclei (blue) staining are shown. Scale bar: 50 µm. 
Sarcomere lengths were determined by line scan and peak-to-peak analysis of the Z-disc. Values are presented as 
means ± SEM, n=5 Control, n=7 TAC. 
As shown in Fig. 7, active RhoA localized predominately at the sarcolemma and to a lesser 
extent at the sarcomere in WT-AMCM. As pressure overload had been shown to perturb 
membrane organization in cardiomyocytes, active RhoA localization was studied in directly 
fixed sham- and TAC-AMCM. In addition, F-actin, myomesin-1, dystrophin and caveolin-3 were 
detected. By confocal microscopy, single cell imaging was performed. Initially, 
RhoA-GTP / F actin double stains were imaged (Fig. 14 A, 14 C). In comparison to sham-
AMCM, a clear disorganization of the periodic active RhoA at the sarcolemma was found in 
TAC-AMCM by surface imaging. TTorg analysis revealed that more cells were present showing 
no regular active RhoA pattern at the cell surface (Fig. 14 B). Similar, the membrane-
associated myomesin-1, dystrophin and caveolin-3 showed less organized distributions at the 
sarcolemma in TAC-AMCM (Fig. 14 C). These results indicate that the organizational changes 
of the sarcolemma, which occur during the process of cardiac remodeling, influences also the 
localization of active RhoA. 
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Fig. 14: Analysis of RhoA-GTP distribution at the sarcolemma of AMCM after transverse aortic 
constriction. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC) intervention and seeded on laminin-coated coverslips. The cells were directly fixed and 
immunofluorescence analyses for the indicated proteins were performed. In addition, F-actin was stained with 
FITC-labelled phalloidin. A) Representative confocal surface view images for RhoA-GTP (green) and F-actin (red) 
are shown. Scale bar 25 µm. Magnification of RhoA-GTP (green), F-actin (red) and merges (from left to right) of the 
surface region of directly fixed sham (left) and TAC (right) AMCM are given below. Scale bar 10 µm. B) TTorg 
analysis of surface view images was performed. In total 10 to 15 cells of 3 independent experiments were analyzed. 
C) Magnifications of confocal center (left) and surface (right) view images of the sarcolemma of sham- and TAC-
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AMCM are depicted. Immunostaining was performed for RhoA-GTP (green) in combination with myomesin-1 (red), 
dystrophin (red) and caveolin-3 (red). F-actin (grayscale) is shown in addition in the center view images. Scale bar 
10 µm. 
Having shown an altered localization of active RhoA in AMCM after TAC, the next aim was to 
analyze the activation of RhoA by different GPCR agonists in AMCM isolated from sham and 
TAC hearts. For that purpose, the isolated cells were cultured for 24 h and then treated with 
the indicated receptor agonist for 90 sec. BSA was used as a control treatment. After immediate 
fixation, active RhoA was detected by immunofluorescence analysis. To investigate potential 
changes confocal overview (10x magnification) and single cell (63x magnification) images 
were generated. Figure 15 A shows the quantification of RhoA-GTP intensities in overview 
images. Those values represent the amount of active RhoA in the whole cell and not from a 
single imaging plane as it is shown and quantified in Fig. 15 B, 15 C and 15 D. 
In sham-AMCM, RhoA could be activated by treatment with ET-1, PE and AngII. Here, the 
highest and most significant responses were observed after application of PE and AngII. In 
TAC cardiomyocytes, RhoA was no longer activated upon the addition of the three agonists. 
Interestingly, ET-1 and PE seemed to have an inhibitory effect on RhoA (Fig. 15 A). Importantly, 
the basal RhoA activity in TAC-AMCM was significantly higher compared to the basal RhoA 
activity in sham-AMCM. 
By quantification of single cell image with a 63x magnification, the same pattern of RhoA 
activation after application of ET-1, PE or AngII (Fig. 15 B, C) was observed in sham 
cardiomyocytes compared to total cell imaging (Fig. 15 A). Both at the sarcolemma and in the 
cytosol, active RhoA showed the highest increase in response to stimulation with PE or AngII. 
However, results obtained for TAC-AMCM from single cell images (63x) compared to overview 
images (10x) differed. The high basal RhoA activity measured in overview images could not 
be seen in single cell images as well as the inhibitory effect of ET-1 and PE on RhoA activity 
in TAC-AMCM was less pronounced. To exclude that these changes resulted from differences 
in the sarcolemmal width, vertical line scans were performed of RhoA-GTP images with 63x 
magnification. In TAC and sham cardiomyocytes, the sarcolemma was found to be ~1.4 µm 
wide (Fig. 15 D). 
The most important difference between the two different imaging modalities was that 
RhoA-GTP intensities in overview images originate from the complete cell depth and include 
the sarcolemma at the top and at the bottom of a cardiomyocyte. In contrast to that, single cell 
images obtained with a magnification of 63x and a confocal pinhole adjusted to one airy unit, 
only represent a single imaging plane with a depth of ~800 nm and do not include signals from 
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top and bottom sarcolemma. Thus, to explain the higher basal RhoA activity observed in 
overview images of TAC-AMCM, volumes of TAC and sham cardiomyocytes were calculated 
based on the mean morphological values given in Fig. 12. The averaged sham-AMCM had a 
volume of 23,372 µm3, averaged TAC-AMCM were significantly larger and had a volume of 
34,592 µm3. Taking those values into account, values for RhoA-GTP intensities in 63x single 
cell images were extrapolated and compared to the intensities obtained from overview (10x) 
images (Fig. 15 E). Those calculations revealed that the significant basal increase of RhoA 
activity in TAC-AMCM could also be reproduced in single cell images. 
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Fig. 15: Analysis of GPCR-dependent RhoA activation in isolated AMCM after transverse aortic 
constriction. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC) intervention and seeded on laminin-coated coverslips. The cells were cultured for 24 h and then 
treated with 100 µM phenylephrine (PE), 50 nM endothelin-1 (ET-1) or 100 nM angiotensin II (AngII) for 90 sec. For 
control BSA was added to the cells. Afterwards the cells were directly fixed and immunofluorescence analysis for 
RhoA-GTP with subsequent confocal imaging was performed. A) Total RhoA-GTP fluorescence from confocal 
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overview images (10x magnification) was quantified and is given as means ± SEM normalized by the area, n=3 with 
>200 cells per group,*p<0.05. B) Representative confocal center view images of RhoA-GTP (green) and additionally 
stained F-actin (red) and cell nuclei (blue) in treated AMCM are shown. Scale bar 25 µm. C) RhoA-GTP fluorescence 
from confocal center view images (63x magnification) was quantified and with help of the wand tool of ImageJ the 
fluorescence of the sarcolemma and the intracellular region was calculated. The intensity values are given as means 
± SEM normalized by the area, n=3 with ≥ 23 cell per group,*p<0.05. D) The width of the RhoA-GTP signal was 
analyzed by line scans. Shown are means ± SEM. E) The fluorescence intensities shown in A) and C) of the sham 
and TAC controls were used to calculate the total relative fluorescent units with help of the calculated cell volumes. 
Shown are the means ± SEM, n=3, *p<0.05. 
Taken together, the basal RhoA activity is increased in TAC compared to sham-AMCM. 
Additionally, ET-1 and PE seem to have an unexpected inhibitory effect on RhoA in TAC-
AMCM. 
Different image analysis approaches revealed an increase of active RhoA after TAC and an 
altered response to different GPCR agonists. For further characterization, the amount of total 
RhoA in isolated AMCM was determined by immunoblot analysis. In addition, the expression 
of α-actinin and caveolin-3 were analyzed. Calsequestrin expression was used to normalize 
the individual values. Representative immunoblots for lysates of sham- and TAC-AMCM and 
the Ponceau S-stained membrane are shown in Fig. 16 A. Quantification of the detected 
proteins revealed a slight, however not significant, increase in α-actinin after TAC. The 
expression of RhoA was significantly decreased after TAC to 59% of the protein amount found 
in sham-AMCM lysate. This was accompanied by a significant decrease of caveolin-3 to 57% 
in AMCM after TAC (Fig. 16 B). 
 
Fig. 16: Analysis of RhoA expression in isolated AMCM after transverse aortic constriction. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC). The cells were directly lysed after isolation and immunoblot analysis was performed. A) 
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Representative Ponceau S staining and the corresponding immunoblots of α-actinin, calsequestrin, total RhoA, and 
caveolin-3 are shown. B) The quantification of the expression levels of α-actinin (left), total RhoA (middle) and 
caveolin-3 normalized to calsequestrin are given as means ± SEM relative to sham, n=3-4 per group, *p< 0.05. 
4.3 Analysis of RhoA activation in adult mouse cardiomyocytes after cholesterol 
depletion 
The observed down-regulation of caveolin-3 and the high basal RhoA activity after TAC implied 
that changes in the sarcolemmal structure could be responsible for alterations in RhoA 
signaling. To prove this hypothesis, AMCM were treated with 0.3 mM methyl-β-cyclodextrin 
(MβCD) for 24 h to deplete the cholesterol out of the membranes and thereby to disrupt lipid 
rafts and caveolae. Afterwards, the cells were treated with 50 nM ET-1 for 90, immediately 
fixed and active RhoA was detected by immunofluorescence. 
The effect of the MβCD treatment on the structure of the membrane and on the distribution of 
the caveolae protein caveolin-3 is shown in Fig. 17 A. Quantification of the respective images 
revealed that in response to cholesterol-depletion, the prominent perinuclear caveolin-3 pool 
in the perinuclear region of cultured cells was redistributed towards the tubular membrane 
system, but no changes were detectable with respect to the pattern regularity and fluorescence 
intensity (Fig. 17 B). Fig. 17 C shows representative confocal images of active RhoA in either 
MβCD- or control-AMCM without treatment or after ET-1 application. Under control conditions, 
ET-1 treatment leads to brighter RhoA-GTP signals especially at the sarcolemma as shown 
before. MβCD-treated AMCM already showed brighter RhoA-GTP signals in the absence of 
ET-1 indicating a higher basal activity induced by membrane disruption. The quantification of 
RhoA activity in those images (Fig. 17 D) revealed that under control conditions, RhoA could 
be significantly activated by ET-1 treatment. On the contrary, ET-1 treatment led to a decrease 
in RhoA activity after cholesterol depletion. These data indicate that although RhoA-GTP 
shows only a very minor co-localization with caveolin-3 (Fig. 6), its regulation by GPCRs is 
dependent on cholesterol and the organization of the sarcolemma. Both, after TAC and MβCD 
treatment, this organization is strongly disrupted and the activity of RhoA is modified. 
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Fig. 17: Analysis of GPCR-dependent RhoA activation in isolated AMCM after MβCD treatment. 
Adult mouse cardiomyocytes (AMCM) were isolated and cultured for 24 h in the presence or absence of 0.3 mM 
methyl-β-cyclodextrin. For RhoA activation 50 nM endothelin-1 (ET-1) was added to the cells for 90 sec, for control 
BSA was added. Afterwards the cells were directly fixed and immunofluorescence analysis for caveolin-3 or RhoA-
GTP with subsequent confocal imaging was performed. A) Representative confocal center view image merges (63x 
magnification) of caveolin-3 (red) and nuclei (blue) are shown. B) Quantification of the percentage distribution of 
caveolin-3 in different cellular compartments is given as bar graph at the left. TTorg analysis of the intracellular 
caveolin-3 pattern is shown in the middle. Mean fluorescence units of complete cells are given at the right. 
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Presented are the means ± SEM, n=3, in total 40 to 50 cells per group, *p<0.05 by 2way ANOVA. C) Representative 
confocal center view images (63x magnification) of RhoA-GTP (green) are shown in combination with actin (red) 
and nuclei (blue). D) Mean RhoA-GTP fluorescence from confocal overview images (10x magnification) was 
quantified and is given as means ± SEM, n=3 with >200 cells per group,*p<0.05 by 1way ANOVA. Scale bars 20 µm. 
4.4 Analysis of active RhoA localization in human adult atrial cardiomyocytes  
All data presented so far, are showing a predominant localization of active RhoA at the 
sarcolemma in adult mouse cardiomyocytes. To confirm that this staining is not restricted 
murine cells, human atrial cardiomyocytes were used for immunofluorescence analysis. The 
cells were kindly provided by Prof. Niels Voigt from the Institute of Pharmacology and 
Toxicology, University Medical Center Göttingen. As shown in Fig. 18, active RhoA showed a 
similar distribution in the human cardiomyocyte compared to AMCM. Besides the predominant 
localization at the sarcolemma, a fine intracellular striation was detectable. Unlike in human 
adult atrial cardiomyocytes, perinuclear granules were detected by confocal imaging with the 
anti-RhoA-GTP antibody. However, as these granules also appeared upon excitation with the 
633 nm laser without having a corresponding fluorophore used, the detected signal is highly 
likely based on autofluorescence of this structure. 
 
Fig. 18: Detection of RhoA-GTP in adult human atrial cardiomyocytes. 
The adult human atrial cardiomyocytes were kindly provided by Prof. N. Voigt. After isolation, the cells were fixed 
and immunofluorescence analysis of active RhoA (green) was performed. The nuclei were stained with DAPI (blue). 
In addition, image acquisition with the 633 nm laser was performed to demonstrate the autofluorescence of the 
perinuclear granules. Shown is a representative cell, scale bar 25 µm. 
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4.5 Analysis of p63RhoGEF localization in adult mouse cardiomyocytes 
The guanine nucleotide exchange factor p63RhoGEF had been demonstrated to be expressed 
in the heart and to be up-regulated after transverse aortic constriction [151]. Moreover, 
p63RhoGEF was shown to mediate the Gq/11-dependent RhoA activation in neonatal rat 
cardiomyocytes (Preliminary results chapter 2) and fibroblasts, as well as in adult rat smooth 
muscle cells [150]. 
To validate the role of p63RhoGEF in AMCM, the localization of the protein had to be analyzed 
first. To do so, several commercially available antibodies were tested by immunoblotting of 
different cell lysates from fibroblasts and cardiomyocytes. Out of four different antibodies, only 
one was able to detect endogenous p63RhoGEF as confirmed by p63RhoGEF-knockout cell 
lysates (data not shown). This antibody, however, strongly detected an additional protein with 
a molecular weight of around 50 kD. By using this antibody in immunofluorescence studies, it 
became apparent that the detected 50 kD protein is likely a tubulin isoform. As these 
experimental obstacles made it impossible to analyze the localization of endogenous 
p63RhoGEF in AMCM, an overexpression approach was chosen for the subsequent 
localization studies. 
Isolated AMCM were transduced with adenoviruses encoding c-myc-tagged full-length 
p63RhoGEF (Ad-p63RhoGEF) or c-myc-tagged N-terminally truncated p63RhoGEF (Ad-
p63∆N). Both viruses additionally led to the expression of EGFP, which allowed the 
identification of efficiently transduced cells. After 48 h of transduction AMCM were fixed and 
immunostained. The localization of full-length or N-terminally truncated p63RhoGEF was 
visualized with an antibody against the c-myc tag. To ensure that the signal coming from the 
anti-c-myc-antibody was specific, AMCM were transduced with a virus encoding EGFP only. 
In these cells no signal could be detected.. 
In general, full-length p63RhoGEF appeared to be mainly associated to membranes including 
the perinuclear ER membrane as well as the outer sarcolemma. This is in line with the by Smith 
and colleagues described localization of the long 618 aa p63RhoGEF variant in adult mouse 
heart tissue [142]. In contrast, truncated p63∆N showed a dominant sarcomeric localization 
and seemed to accumulate at the intercalated disk when higher expressed (Fig. 19 B). For 
quantification, the fluorescence distribution between different cellular compartments in AMCM 
with low and high transduction efficiency was analyzed. The cells were chosen based on their 
strengths of the EGFP signal. The comparison of cells expressing low and high amounts of 
full-length p63RhoGEF showed a similar percentage of the protein in the perinuclear region 
but differed significantly in the intracellular and sarcolemmal compartment. When compared to 
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lowly transduced cells, highly transduced cells showed a lower and higher percentage of the 
protein in the intracellular space and sarcolemma, respectively (Fig. 19 A). In contrast, the 
percentage of p63∆N located at the sarcolemma was not dependent on the expression height. 
It is important to mention that in this analysis the sarcolemma did not contain the intercalated 
disc region as in this region a higher percentage of protein was present in highly transduced 
cells. Similar as for the full-length protein, the fraction of p63∆N in the intracellular compartment 
was reduced in strongly overexpressing cells (Fig. 19 B). 
 
Fig. 19: Relation of p63RhoGEF transduction efficiency and localization in AMCM. 
Transduced AMCM were cultured for up to 36 h with adenoviruses encoding for EGFP, p63RhoGEF or p63∆N. 
A) Representative confocal images for AMCM with low (top) and high (bottom) transduction efficiency for full-length 
p63RhoGEF and corresponding quantification of p63RhoGEF localization. B) Representative confocal images for 
AMCM with low (top) and high (bottom) transduction efficiency for N-terminally truncated p63∆N and corresponding 
quantification of p63∆N localization. The p63RhoGEF and p63∆N localization were visualized with an anti-c-myc 
antibody. Data are presented as means ± SEM for 30 cells per group, *p<0.05. Scale bars: 25 µm. 
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Next to the analysis of the localization pattern of p63RhoGEF and its truncated mutant p63∆N, 
co-localization studies were performed. Therefore, the transduced AMCM were additionally 
immunostained for α-actinin (Fig. 20 A, green), RhoA (Fig. 20 B, green), active RhoA 
(Fig. 20 C, green), and caveolin-3 (Fig. 20 D, green). The representative confocal images of 
complete cells in Fig. 16 show an overlay of the four channels with DAPI in blue, the additional 
protein of interest in green and c-myc in red. Magnifications additionally show the individual 
color channels and EGFP for positive transduction in grey. These multi-color images are shown 
and compared for AMCM transduced with all three viruses. As expected, AMCM transduced 
with the control virus (EGFP) exhibited no signal for c-myc since that virus does not express a 
c-myc-tagged protein. 
Co-detection of α-actinin demonstrated that the sarcomeric regularity was not disturbed by the 
transduction with the different viruses and the respective expression of p63RhoGEF variants 
as shown in Fig. 20 A. AMCM transduced with all three viruses had a clear and regular striated 
pattern. A partial overlap with p63∆N was visible at the z-disc, but no co-localization was found 
for the full-length protein (Fig. 20 A). Similar results were obtained for total RhoA as the protein 
was regularly distributed at the sarcomere in AMCM transduced with all three viruses. A partial 
co-localization with p63∆N was detectable in the sarcomere. An additional, moderate 
perinuclear localization became apparent in p63RhoGEF overexpressing cells (Fig. 20 B). As 
observed before, active RhoA (RhoA-GTP) located in all three conditions predominantly at the 
sarcolemma (Fig. 20 C). This membrane distribution of RhoA-GTP was comparable for AMCM 
transduced with the three different viruses. Full-length p63RhoGEF seemed to co-localized at 
the sarcolemma with active RhoA and p63∆N showed an overlap at the intercalated disc. The 
membrane protein caveolin-3 showed strong signals at the sarcolemma and in the perinuclear 
region for AMCM transduced with all three viruses (Fig. 20 D). Clear co-localization with full-
length p63RhoGEF in these membrane compartments was found, whereas p63∆N mainly 
showed an overlap at the former intercalated disc. 
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Fig. 20: Analysis of p63RhoGEF localization in AMCM. 
Isolated adult mouse cardiomyocytes (AMCM) were transduced for up to 48 h with recombinant adenoviruses 
encoding EGFP only (Ad-EGFP), or EGFP and full-length, c-myc-tagged p63RhoGEF (Ad-p63RhoGEF), or EGFP 
and N-terminally, c-myc-tagged truncated p63RhoGEF (Ad-p63ΔN). The localization of p63RhoGEF was visualized 
by immunofluorescence with help of an anti-c-myc antibody (red). Transduced cells were identified by EGFP (gray 
scale) expression. Co-staining of nuclei with DAPI (blue) was performed. To characterize the localization of 
p63RhoGEF, the following proteins were additionally analyzed by immunofluorescence: A) α-actinin (green), 
B) RhoA (green), C) active RhoA (green) and D) caveolin-3 (green). The representative images of complete cells 
show an overlay of all four channels. Magnifications (below) show all individual channels and overlay excluding the 
EGFP signal. Scale bar: 25 µm or 10 µm. 
Due to the observed co-localization of overexpressed full-length p63RhoGEF and active RhoA 
at the sarcolemma in center view images (Fig. 20 C), surface view imaging was performed in 
order to study the pattern of both proteins. As shown in Fig. 21 A, the overexpressed 
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p63RhoGEF showed no overall co-localization with active RhoA. The distribution of 
p63RhoGEF at the surface was in general patchier than of active RhoA. The degree of signal 
overlaps was low and mainly restricted to areas of the former intercalated discs (Fig. 21 A). 
Next, active RhoA levels were detected in 10x overview images. Unfortunately, application of 
the GPCR ligands ET-1, PE and AngII did not show any positive responses in control-
transduced cells and only minor changes in p63RhoGEF overexpressing cells (Fig. 21 B). If 
the observed unresponsiveness of the transduced cells was a consequence of the adenoviral 
transduction, the long culture time or both is difficult to assess. 
 
Fig. 21: Sarcolemmal localization of p63RhoGEF and active RhoA in AMCM. 
Isolated adult mouse cardiomyocytes (AMCM) were transduced for up to 48 h with recombinant adenoviruses 
encoding EGFP only (Ad-EGFP) or EGFP and full-length, c-myc-tagged p63RhoGEF (Ad-p63RhoGEF). A) The 
localization of p63RhoGEF and active RhoA were visualized in Ad-p63RhoGEF transduced AMCM by 
immunofluorescence with help of an anti-c-myc antibody (red) and a RhoA-GTP antibody (green). Confocal surface 
view images were taken. Shown are two representative cells. Scale bar 25 µm B) The transduced cells were treated 
after 48 h with 50 nM endothelin-1 (ET-1), 100 µM phenylephrine (PE) or 100 nM angiotensin II (AngII) for 90 sec. 
For control BSA was added to the cells. Afterwards the cells were directly fixed and immunofluorescence analysis 
for RhoA-GTP with subsequent confocal imaging was performed. Total RhoA-GTP fluorescence from confocal 
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overview images (10x magnification) was quantified and is given normalized to the area as individual vales of 85 to 
135 cells per condition. The means are indicated in red. 
4.6 Regulation of membranous structures by p63RhoGEF overexpression in adult 
mouse cardiomyocytes 
Co-localization analysis of p63RhoGEF and caveolin-3 in confocal center view images 
revealed (Fig. 22 A) that when p63RhoGEF is relatively low expressed, its correlation with 
caveolin-3 is higher than vice versa. This is mainly due to its predominant perinuclear 
localization and the lacking sarcolemmal localization. In highly expressing cells both proteins 
co-localize to a similar extent to each other, which can be explained by the increasing 
localization of p63RhoGEF at the sarcolemma (Fig. 22 B). However, by analyzing surface view 
images of both proteins, the obtained correlation coefficients were remarkable lower as those 
detected in center view images (Fig. 22 C). This is mainly based on the missing signal 
resolution at the sarcolemma in center view images. In addition to the degree of co-localization 
of both proteins, the impact of p63RhoGEF on the distribution of caveolin-3 was assessed. 
Interestingly, the accumulation of p63RhoGEF in the perinuclear region, which is independent 
of its expression height, led to an increased accumulation of caveolin-3 in the same area. The 
observed increase of p63RhoGEF at the sarcolemma in highly transduced cells did not result 
in higher caveolin-3 levels, instead its intracellular amount was decreased (Fig. 22 D). 
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Fig. 22: Analysis of the co-localization of p63RhoGEF and of caveolin-3 in AMCM. 
Isolated adult mouse cardiomyocytes (AMCM) were transduced for up to 48 h with recombinant adenoviruses 
encoding for EGFP only (Ad-EGFP), or for EGFP and for full-length, c-myc-tagged p63RhoGEF (Ad-p63RhoGEF). 
The localization of p63RhoGEF and caveolin-3 were visualized by immunofluorescence with help of a c-myc 
antibody (red) and an anti-caveolin-3 antibody (green), respectively. A) Representative center view images of 
p63RhoGEF and caveolin-3 are given of control transduced (Ad-EGFP) and Ad-p63RhoGEF-transduced cells 
showing low and high p63RhoGEF expression. The merges are presented below. Scale bar 20 µm. B) Co-
localization of p63RhoGEF and caveolin-3 was analyzed by the ImageJ plugin Coloc2 in center view images. M1 
reflects the co-localization of p63RhoGEF with caveolin-3 and M2 of caveolin-3 with p63RhoGEF. In total 20 to 25 
cells were analyzed from 3 independent transduction experiments. Given are the means ± SEM, *p<0.05. 
C) Representative magnifications of surface view images are given of cells highly expressing p63RhoGEF. Co-
localization of p63RhoGEF and caveolin-3 was analyzed by the ImageJ plugin Coloc2 in 4 cells in three different 
areas. The single values are shown together with their mean. D) The localization of caveolin-3 (left) and p63RhoGEF 
(right) was analyzed in control transduced cells (for caveolin-3 analysis, p63RhoGEF-no) and cells expressing low 
(p63RhoGEF-low) and high (p63RhoGEF-high) amounts of p63RhoGEF. In total 20 to 25 cells of 3 independent 
transduction experiments were analyzed. Given are the percentages as means ± SEM of the respective proteins in 
each compartment, *p<0.05. 
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As p63RhoGEF expression influenced the distribution of the membrane protein caveolin-3, its 
impact on the intracellular secretory membrane system was analyzed. 
First, the co-localization of both p63RhoGEF constructs with proteins containing the ER 
retention and targeting motif KDEL (lysine - aspartic acid - glutamic acid - leucine) was 
investigated. Surprisingly, this revealed a very strong overlap between full-length p63RhoGEF 
and KDEL-containing proteins as well as between p63∆N and KDEL-proteins (Fig. 23 A). 
Quantification of the co-localization demonstrated that p63RhoGEF and KDEL-proteins co-
localized to a similar extent to each other, whereas the KDEL-proteins showed a higher 
correlation to p63∆N than vice versa (Fig. 23 B). Although a certain degree of co-localization 
was also found for caveolin-3, the surprising increase in KDEL-signal intensity in cells 
overexpressing the two p63RhoGEF constructs compared to control transduced cells was 
unusual. To further investigate this phenomenon, immunoblot studies were performed. 
However, with the used antibody no difference in the detected KDEL-proteins were found (data 
not shown), but instead the p63RhoGEF constructs could be detected. This is exemplarily 
shown for p63∆N in Fig. 23 C. Thus, it can be assumed that the observed co-localization results 
from an experimental artefact. The reason for this artefact could lay in the recognition of the 
antibody of the C-terminal EDEL sequence of p63RhoGEF. 
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Fig. 23: Analysis of the co-localization of p63RhoGEF and of KDEL-proteins in AMCM. 
Isolated AMCM were transduced for up to 48 h with recombinant adenoviruses encoding EGFP only (Ad-EGFP), 
EGFP and full-length c-myc-tagged p63RhoGEF (Ad-p63RhoGEF), or EGFP and N-terminally truncated c-myc-
tagged p63RhoGEF (Ad-p63ΔN). The localization of c-myc tagged p63RhoGEFand p63∆N were detected with an 
anti-c-myc antibody, KDEL proteins were detected with an antibody against the KDEL-motif. Immunostained AMCM 
were visualized by confocal microscopy and confocal images were used for co-localization analyses. A) The 
representative images of complete cells show an overlay of all four channels. Magnifications (below) show all 
individual channels and overlay excluding the EGFP (gray scale) signal. Scale bar: 25 µm or 10 µm. B) Co-
localization of p63RhoGEF constructs and KDEL-proteins was analyzed by the ImageJ plugin Coloc2 in center view 
images. M1 reflects the co-localization of the respective p63RhoGEF construct with KDEL and M2 of KDEL with the 
p63RhoGEF construct. In total 31 cells per condition were analyzed from 3 independent transduction experiments. 
Given are the means ± SEM, *p<0.05. C) Representative Immunoblots of c-myc and KDEL in cell lysates from 
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AMCM transduced either with Ad-EGFP or with Ad-p63∆N. For immunoblotting, the same antibodies were used as 
for the immunostains shown in A) The arrows indicate the specific p63∆N bands. 
Second, localization analysis of the cis-Golgi matrix protein GM-130 was performed together 
with the p63RhoGEF constructs. Independent of the used adenoviral constructs, GM-130 was 
found in discrete speckles in the perinuclear region and in speckles distributed over the cells 
(Fig. 24 A). Furthermore, GM-130 was located close to p63RhoGEF accumulations in the in 
the Ad-p63RhoGEF-transduced cells. Quantification of the particle size revealed a significant 
decrease from 0.57 µm² to 0.52 µm² for p63RhoGEF and p63∆N compared to control AMCM 
expressing EGFP only. The average particle number per cell in one center view imaging plane 
changed significantly from 42 particles in AMCM overexpressing EGFP only, to 45 particles for 
p63∆N and to 58 particles per AMCM in p63RhoGEF transduced AMCM. Moreover, 
p63RhoGEF expression led to a slight, but significant reduction of GM-130 in the perinuclear 
region. Instead more GM-130 could be detected in the cell periphery (Fig. 24 B). 
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Fig. 24: Analysis of the co-localization of p63RhoGEF and of the cis-Golgi matrix protein GM-130 
in AMCM. 
Isolated adult mouse cardiomyocytes (AMCM) were transduced for up to 48 h with recombinant adenoviruses 
encoding for EGFP only (Ad-EGFP), or for EGFP and for full-length, c-myc-tagged p63RhoGEF (Ad-p63RhoGEF), 
or for EGFP and for N-terminally, c-myc-tagged truncated p63RhoGEF (Ad-p63ΔN). The localization of p63RhoGEF 
was visualized by immunofluorescence with the help of a c-myc antibody (red) and the Golgi apparatus with an 
antibody against the cis-Golgi matrix protein GM-130. Transduced cells were identified by EGFP (gray scale) 
expression. Co-staining of nuclei with DAPI (blue) was performed. A) Representative center view confocal images 
are shown as an overlay of all four channels. Magnifications (below) show all individual channels and overlay 
excluding the EGFP signal. Scale bar: 25 µm. B) Analysis of the Golgi particle size (upper) and the particle number 
(middle) was performed with the help of the particle analysis tool of ImageJ. In total 35 to 45 cells per group were 
analyzed. The distribution of GM-130 was analyzed by its fluorescence in the perinuclear region (selection of the 
nuclei with 2.5 µm enlargement) and in the rest of the cells. In total 20 to 25 cells per group were analyzed. All 
values are given as means ± SEM, n=4, *p<0.05. 
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4.7 Regulation of cell morphology by p63RhoGEF overexpression in adult mouse 
cardiomyocytes 
Another question that had to be addressed was the impact of the different p63RhoGEF 
constructs on the morphology of AMCM. To answer that question quantitatively, AMCM of three 
individual mice were isolated, adenovirally transduced with the three different constructs 
(EGFP only, p63RhoGEF and p63∆N), cultured for up to 36 h, fixed and immunostained. By 
visualizing the EGFP signal with a confocal microscope using a 10x objective, several cells 
could be imaged simultaneously. Imaging and quantitative analysis of AMCM overexpressing 
EGFP only revealed no direct correlation between individual transduction efficiency (RFU of 
EGFP) and cell size (area and length) (Fig. 25 A). 
The representative confocal images in Fig. 25 B show α-actinin (green) and c-myc (red) 
immunostains of AMCM overexpressing EGFP only, p63∆N or p63RhoGEF. For the EGFP only 
construct no signal was expected because of the missing c-myc tag. These representative 
confocal images visualize that AMCM overexpressing p63RhoGEF appear larger than AMCM 
overexpressing EGFP only or p63∆N. The representative immunoblots of AMCM lysates on 
the right confirm overexpression of the three different constructs. 
To validate the size of AMCM overexpressing p63RhoGEF, cross-sectional area, length and 
depth were quantitatively analyzed in AMCM overexpressing either EGFP only, p63∆N or 
p63RhoGEF. These data were summarized as bar graphs in Fig. 25 C. As expected from the 
representative confocal images (Fig. 25 B), average data show that AMCM cross-sectional 
area is moderately larger and smaller in cells overexpressing p63RhoGEF and p63∆N, 
respectively. However, only the difference between the two different p63RhoGEF constructs 
was significant. The averaged data of cell length for all three constructs show a significant 
increase for p63RhoGEF compared to EGFP only and p63∆N. Deviating from these results, 
the cell depth seems not to be influenced by the overexpression of p63RhoGEF. In summary, 
these data indicate that only overexpression of p63RhoGEF, but not of EGFP alone or of 
p63∆N, has an impact on cell morphology and leads to an increase in cell size. 
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Fig. 25: Impact of the adenovirus-mediated expression of p63RhoGEF on the morphology of WT-
AMCM. 
AMCM were transduced with adenoviruses encoding for EGFP, for full-length p63RhoGEF or for N-terminally 
truncated p63RhoGEF (p63∆N) and cultured for up to 36 h. A) (left) Representative fluorescence image of AMCM 
transduced with adenovirus overexpressing EGFP only. Individual EGFP positive cells show different transduction 
efficiencies as indicated by the intensity of the green signal. (right) Correlation of transduction efficiency measured 
by relative fluorescence units (RFU) with area (µm²) and length (µm) of individual AMCM (scale bar 100 µm). The 
red dashed line represents the fluorescence threshold of positively transduced cells. Values underneath the line are 
based on autofluorescence of the cells. B) Representative confocal images of α-actinin (green) and c-myc (red) in 
adenovirally transduced AMCM (left) and the corresponding representative immunoblots of the cell lysates (right) 
are shown. Overexpression of p63RhoGEF and p63∆N was confirmed in an immunoblot with an anti-c-myc 
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antibody. Scale bar 25 µm. C) Analysis of the cross-sectional area (left), cell length (middle) and cell depth (right) 
of EGFP, p63RhoGEF and p63∆N transduced AMCM measured in confocal images with 10x magnification are 
depicted. The values are given as means ± SEM. For area and length analysis: n=3, >200 cells *p<0.05; for depth 
analysis: n=3, >70 cells. 
Having shown that overexpression of p63RhoGEF in AMCM increased cell size, especially in 
length (as shown in Fig. 25 C), the subsequent question was if that morphological change also 
has an influence on sarcomeric architecture. Although already briefly mentioned, the 
sarcomeric structure was further quantitatively analyzed here. For that purpose, AMCM were 
transduced with viruses encoding for EGFP only, for p63∆N or for p63RhoGEF. Then, the cells 
were fixed and stained for F-actin. By peak-to-peak distance measurements of line scans, the 
average sarcomeric length of transduced AMCM was determined. Comparison of average 
sarcomere lengths in AMCM overexpressing either EGFP only, N-terminally truncated 
p63RhoGEF or full-length p63RhoGEF revealed no detectable difference indicating that 
overexpression of the two different p63RhoGEF constructs does not influence the sarcomeric 
length in AMCM (Fig. 26). 
 
Fig. 26: Analysis of sarcomere lengths in WT-AMCM overexpressing p63RhoGEF or p63∆N. 
AMCM were transduced with adenoviruses encoding for EGFP, for full-length p63RhoGEF or for N-terminally 
truncated p63RhoGEF (p63∆N) and cultured for up to 36 h. α-actinin was stained and confocal imaging was 
performed. (Left) Representative α-actinin images in gray scale are given. (Right) Corresponding quantification by 
peak-to-peak analysis of the sarcomeric lengths are depicted as means ± SEM, n=13 cells per group. Scale bar: 
25 µm. 
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Based on the detected morphological changes in AMCM transduced with adenoviruses 
encoding for EGFP only, p63RhoGEF or p63∆N (Fig.25, 26), the impact of the observed cell 
growth on the nuclear dimensions was analyzed. For all three adenoviruses, area, circularity 
and roundness of nuclei stained with DAPI were measured using the wand tool of ImageJ 
(Fig. 27 A). Interestingly, the average nucleus area significantly decreased from 69 µm² for 
EGFP only to 64 µm² for p63RhoGEF and 53µm² for p63∆N. However, nuclei circularity, the 
ratio between area and perimeter, did not change. On the other hand, nuclear roundness, 
which refers to the major nuclear axis, was significantly changed. A value of 1 for roundness 
and circularity would describe a perfect circle. For EGFP only, a flat oval shape was depicted 
by the measured roundness of 0.38. In comparison to that, the pattern changed significantly 
to oval for p63RhoGEF (with a roundness of 0.43) and p63∆N (with a roundness of 0.5) 
(Fig. 27 B). 
 
Fig. 27: Influence of p63RhoGEF on nuclei morphology in AMCM. 
Adult mouse cardiomyocytes were cultured and transduced for up to 36 h with adenoviruses encoding EGFP, full-
length p63RhoGEF (p63RhoGEF) and the N-terminal truncated construct (p63∆N). A) Graphical illustration of an 
AMCM with two nuclei and magnification with perimeter and major axis highlighted is shown. Equations for the 
calculation of nucleus circularity and roundness measured with ImageJ are given. B) Analysis of nucleus area (left), 
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circularity (middle) and roundness (right) in EGFP-, p63RhoGEF- and p63∆N-transduced AMCM measured in 
fluorescence images with 20x magnification are presented as means ± SEM, n=6 ,≥80 cells *p<0.05. 
The data presented so far provided an understanding of the expression height dependent 
localization of p63RhoGEF and the resulting morphological changes in AMCM. By 
overexpressing the N-terminally truncated construct of p63RhoGEF, the importance of the N-
terminus for the proper localization at the sarcolemma could be shown. For full-length 
p63RhoGEF a sarcolemmal, perinuclear and partially sarcomeric localization was found. For 
p63∆N a predominant localization at the intercalated discs and in the sarcomere was detected. 
Furthermore, an influence of p63RhoGEF on the localization of membrane proteins like 
caveolin-3 and on the morphology of the Golgi apparatus was identified. Finally, an increase 
in cell volume, reflected by an increase in cell length and no changes in area and depth, in 
p63RhoGEF overexpressing cells was identified which was accompanied by a rounding of the 
cell nucleus. p63∆N did not influence the cell volume but reduced the nucleus area and 
increased the nuclear roundness. 
4.8 Influence of the genetic deletion of p63RhoGEF on heart and cardiomyocyte 
morphology 
The results obtained with transduced AMCM, led to the question which consequence a lack of 
p63RhoGEF in AMCM might have. To answer this question, a p63RhoGEF knockout mouse 
was generated. By integration of flox-sites flanking exons 1 and 2 of the p63RhoGEF allele in 
the genome and subsequent mating with a mouse line expressing Cre-recombinase, the 
p63RhoGEF knockout mouse line was generated. 
Prior to the cellular analysis, the morphological properties of the hearts were investigated by 
echocardiography, which was kindly performed by the service unit from the SFB 1002 at the 
University Medical Center Goettingen. For that purpose, hearts (Fig.28 A) from 10-12 week old 
male mice were investigated for anterior and posterior wall thickness and for the cross-
sectional area of the left ventricular lumen during systole and diastole. These values are 
indicators for hypertrophy and dilation of the heart. Male wild-type mice were compared with 
male mice heterozygous (HET) and homozygous (KO) for the p63RhoGEF knockout. In 
general, no significant differences were found in all parameter investigated in the three mouse 
lines. By trend, the heterozygous mice showed slightly thinner wall dimensions as well as 
increased ventricular areas in systole and diastole pointing to mild dilation of the ventricle 
(Fig. 28 B). This is in line with data of Dr. Anita Ongherth, who demonstrated that the systolic 
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and diastolic volume of these mice is significantly higher compared to wildtype mice 
(http://hdl.handle.net/11858/00-1735-0000-002B-7CC9-0). 
 
Fig. 28: Analysis of the cardiac dimensions in mice with p63RhoGEF deletion. 
The basal cardiac dimension of 10-12 weeks old male mice was determined by echocardiography. A) Schematic 
cross section of the heart is shown for better orientation. Indicated are the right (RV) and left (LV) ventricles and the 
anterior-posterior orientation. B) Average values of anterior wall thickness in diastole (AWthD), anterior wall 
thickness in systole (AWthS), posterior wall thickness in diastole (PWthD), posterior wall thickness in systole 
(PWthS), area of the cross sectional left ventricular lumen in diastole (Area D) and area of the cross sectional left 
ventricular lumen in systole (Area S) are shown as means ± SEM from 28 wildtype (WT), 16 heterozygous (HET) 
and 43 homozygous knockout (KO) animals. 
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Subsequently, the AMCM were isolated using a modified Langendorff perfusion system and 
fixed after 1 h or 24 h in culture. The dimensions of the cells were quantified using ImageJ. 
For cardiomyocytes length, no significant differences were measured between all three 
genotypes. In addition, during 24 h in culture the cell length did not change over time. In 
contrast to cardiomyocyte length, the cell depth was slightly smaller in AMCM from HET and 
KO mice. Strikingly, all three genotypes showed a slight reduction of cardiomyocytes depth for 
cells cultured for 24 h (Fig. 29 A). Directly fixed HET and KO AMCM were 6% flatter in average 
depth compared to control AMCM. In addition, AMCM cultured for 24 h lost 6% of depth for 
HET, 10% for WT and 16% for KO (Fig. 29 B). 
The average area of directly fixed HET and KO AMCM was 4% larger compared to the controls. 
Furthermore, the average area of all AMCM significantly decreased significantly during 24 h of 
culture, by 10% in HET, 11% in WT and 12% in KO (Fig. 29 C). 
To better understand the morphological changes in cell culture and in the different genotypes, 
the surface and volume of an elliptical barrel was calculated based on the measured 
parameters. Again, the culture-dependent reduction was evident for both the cellular volume 
and the associated surface. Cardiomyocytes from KO animals had the smallest average cell 
volume with 19600 μm³ compared to control with 21800 μm3 after 24 h of culture (Fig. 29 E). 
The calculated average cell surface was also strongly reduced after 24 h of culture with 6600 
μm² compared to directly fixed WT cardiomyocytes with 6800 μm² (Fig. 29 D). In summary, 
cardiomyocytes of all three genotypes become smaller after 24 h in culture. Specifically, 
cardiomyocytes of p63RhoGEF KO mice developed a flatter cell shape in culture. In line with 
these results, the cell surface and volume were clearly smaller. 
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Fig. 29: Influence of p63RhoGEF deletion on the cellular morphology of AMCM. 
Analysis of isolated AMCM from 10-20 week old male mice was performed. Cardiomyocytes from all three 
genotypes (wildtype (WT) heterozygous (HET) and knockout (KO)) were isolated via modified Langendorff perfusion 
system and seeded on laminin coated glass coverslips. Cells were either fixed after 1 h (direct) or after 24 h in 
culture. Dimensions were measured with ImageJ. Bar graphs summarize average values for A) length, B) depth, 
C) calculated area, D) calculated surface, and E) calculated volume of AMCM cultured for 1-24 h of various 
genotypes. Given are the values as means ± SEM, n>3, *p<0.05, length: 293-1345 cells, depth: 30 cells, area: 235-
1040 cells. 
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As previously demonstrated, overexpression of p63RhoGEF had a significant influence on the 
nucleus morphology (Fig. 27 B). This raised the question if deletion of p63RhoGEF has an 
influence on the nuclear morphology as well. In line with results of the significant reduction of 
the area of AMCM cultured for 24 h, demonstrated in Fig. 29, nucleus morphology was 
analyzed in WT-, HET- and KO-AMCM. A significant reduction of the averaged nuclei area up 
to 21 % (WT 14%, HET 17%, KO 21%) was shown after 24 h in culture. Furthermore, AMCM 
with a full deletion of p63RhoGEF (KO) showed a significantly smaller nucleus area, both in 
directly fixed AMCM and in AMCM cultured for 24 h compared to WT AMCM. In addition, the 
roundness as an indicator for the flattening of the nuclei significantly decreased in WT-AMCM, 
but not in HET- or KO-AMCM over time (Fig. 30). 
 
Fig. 30: Influence of p63RhoGEF deletion on nucleus morphology in AMCM. 
Cardiomyocytes were isolated from 10-20 week old male mice. Cells were either fixed after 1 h (direct) or after 24 
h in culture. Subsequently, cell nuclei were stained with DAPI. For quantification of the nucleus area and the nucleus 
roundness the ImageJ wand tool and function analyze particle were used. Parameters were measured in 
fluorescence images with 20x magnification (means ± SEM, n=6 ,≥74 cells *p<0.05). 
To investigate if the observed changes in the KO-AMCM reflect the morphology of these cells 
in the myocardium, cell dimensions were analyzed in paraffin-embedded tissues, which were 
a kind gift of Dr. Anita Ongherth. The diameter of the cardiomyocytes was determined in tissue 
areas showing a cross section of cardiomyocytes. Based on the obtained area and perimeter 
data, the diameter of the cells was determined for better comparison. Similar as shown for the 
depth of the isolated AMCM, the mean diameter of KO-AMCM was significantly smaller when 
compared to the diameter of WT-AMCM (Fig. 31 A). Next, the size of the nuclei was analyzed 
in tissue areas showing a longitudinal section of cardiomyocytes. Cardiomyocyte nuclei were 
identified based on their localization with the help of the FITC-WGA stain as well as by their 
characteristic DAPI pattern (Fig. 31 B). As shown in Fig. 27 a cardiomyocyte nucleus is 
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characterized by its chromatin ring at the periphery and the strong DAPI-positive clusters inside 
the nucleus [158]. 
 
Fig. 31: Influence of p63RhoGEF deletion on cell and nucleus morphology of AMCM in the 
myocardium. 
Hearts from 12 to 14 weeks old male wildtype (WT) and p63RhoGEF knockout (KO) mice were isolated, fixed, 
paraffin-embedded and cut in 7 µm thick sections. The sections were stained with FITC-labeled wheat germ 
agglutinin (WGA) and DAPI. Fluorescence imaging was performed. A) Representative cross-sectional merged 
images of the heart sections are shown. The cardiomyocytes were encircled in ImageJ, and based on the obtained 
areas and perimeters, the diameters of the cardiomyocytes were calculated. In total 800 to 1200 cells from 8 to 10 
mice per group were analyzed. Given are the values as means ± SEM, *p<0.05 assessed by unpaired t-test. 
B) Representative longitudinal DAPI (gray scale) and merged images of the heart sections are shown. The nuclei 
of the cardiomyocytes were identified due their localization and typical morphology and were encircled in ImageJ. 
The areas and corresponding roundness values are given as means ± SEM. In total 350-450 cells from 8 to 10 
mice per group were analyzed, *p<0.05 assessed by unpaired t-test. 
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4.9 Influence of the genetic deletion of p63RhoGEF on RhoA activity in adult 
mouse cardiomyocytes 
Next, basal RhoA activity was investigated in freshly isolated AMCM from all three genotypes. 
With the help of a biochemical RhoA activation assay and by immunoblotting active RhoA, total 
RhoA and calsequestrin were analyzed. Both, active RhoA and total RhoA were normalized to 
calsequestrin, and active RhoA to total RhoA. In KO-AMCM a significant increase of more than 
50% of active RhoA was found compared to WT- and HET-AMCM, when normalized by 
calsequestrin. Additionally, total RhoA showed a gradual and significant increase of up to 80% 
in KO-AMCM when normalized by calsequestrin. Thus, the ratio of active RhoA to total RhoA 
was unchanged in HET- and KO-AMCM compared to WT-AMCM (Fig. 32 A). In parallel, active 
RhoA levels were investigated by immunofluorescence analysis. Confocal center view images 
were prepared and the fluorescence at the sarcolemma and inside the cell measured. Similar 
as found by biochemical analysis, an increase in of around 50% was found at the sarcolemma 
of KO-AMCM. The little amount of active RhoA in the intracellular compartment was not 
change. To further validate this increase, the percent change of active RhoA at the sarcolemma 
and in the intracellular space was calculated, confirming the increased amount of RhoA-GTP 
at the sarcolemma in KO-AMCM (Fig. 32 B). 
 
Fig. 32: Influence of p63RhoGEF deletion on the basal level of active RhoA in AMCM. 
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Freshly isolated AMCM from wildtype (WT), heterozygous (HET) and homozygous (KO) male p63RhoGEF 
knockout mice were used for the analysis. A) AMCM were directly stored after isolation at -80°C as pellet. RhoA-
GTP levels were determined by the G-Lisa activity assay. Calsequestrin and total RhoA expression was determined 
in cell lysates by immunoblot analysis. Mean values of RhoA-GTP normalized to calsequestrin (left) and total RhoA 
(right), as well as of total RhoA normalized to calsequestrin (middle) were calculated. Data are presented as means 
± SEM, n=3, *p<0.05. B) AMCM were directly fixed after isolation. Active RhoA (green) was detected with the anti-
RhoA-GTP antibody (green) and actin with TRITC-labeled phalloidin (red). Confocal center view imaging was 
performed. Representative images are depicted. Active RhoA levels at the sarcolemma (S) and in the rest of the 
cell (I) were quantified and are given normalized to the area (left). The distribution of the total cell signal was 
calculated for the sarcolemma and the intracellular space (right). In total 15 cells per genotype were analyzed. The 
values are given as means ± SEM, n=3, *p<0.05. 
Continuing the investigation of p63RhoGEF-dependent effects, cardiomyocytes from WT, HET 
and KO mice were isolated and cultured for 24 h, treated with the GPCR agonists ET-1, PE 
and AngII for 90 sec, and immunostained for active RhoA. Imaging was performed in two 
magnification steps. In the first step, the overall cellular activity of RhoA was imaged with a 10x 
objective (Fig. 33 A). In the second step, single cell RhoA activity was observed with a 63x 
objective resulting in 800 nm thick layers of the cell center plane (Fig. 33 B). 
In wild-type AMCM, a significant RhoA activation with GPCR agonists was found in response 
to all three treatments as revealed by analysis of the 10x overview images (Fig. 33 A). The 
most efficient activation was induced by ET-1 application in this set of experiments. ET-1 
treatment was also sufficient to induce RhoA activation inside the cells (Fig. 33 B). Interestingly, 
none of the GPCR agonist was able to induce RhoA activation in the HET- and KO-AMCM 
(Fig. 33 A, B). Similar as found in TAC-AMCM as well as in MβCD-treated AMCM, ET-1 and 
PE application led to a reduction in RhoA activation in HET- and KO-AMCM, at least when 10x 
overview imaging was performed. Moreover, the increased basal RhoA activity in KO-AMCM 
seemed to be preserved during the culture (Fig. 33). 
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Fig. 33: Analysis of RhoA activation in AMCM with p63RhoGEF deletion. 
AMCM were isolated from 10-20 week old male wild-type (WT), heterozygous (HET) and knockout (KO) mice and 
cultured for 24 h. Then the cells were treated with ET-1, PE or AngII for 90 sec. For control, AMCM were treated 
with BSA for 90 sec. After fixation, cells from all groups were stained for RhoA-GTP (green) and actin (red) as well 
as with DAPI (blue). A) Representative confocal 10x overview images (left) of RhoA-GTP of treated WT-AMCM are 
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shown. Bar graphs (right) summarize average values of the determined RhoA-GTP intensities per area. Data are 
shown as means ± SEM, n=3, 259-390 cell per group, *p< 0.05. Scale bar: 100 µm. B) Representative confocal 
63x center view images (left) of treated AMCM stained for RhoA-GTP (green), F-actin (red) and cell nuclei (blue) 
are presented. Scale bar 25 µm. Bar graphs on the right show the quantification of the mean RhoA-GTP 
fluorescence per area ±SEM at the sarcolemma (top) and in the cytosol (bottom), n≥3 mice, ≥ 18 cells per group, 
*p < 0.05. 
4.10 Influence of the genetic deletion of p63RhoGEF on the regulation of 
membranous structures 
As by overexpression of p63RhoGEF, changes in the distribution of caveolin-3 were identified, 
the impact of the p63RhoGEF deletion was studied next. For that purpose, AMCM of all three 
genotypes were isolated and fixed directly after one hour of culture. Immunostaining of the 
cells for caveolin-3 and DAPI was performed (Fig. 34). Analysis of the caveolin-3 distribution 
at the sarcolemma and in the intracellular space showed no significant changes between the 
different genotypes (Fig. 34 A). After ImageJ processing and extraction of the membrane 
system, the orientation of caveolin-3 positive membranes were analyzed. Representative 
confocal images (top) and extracted skeleton (below) showed no visible differences between 
the different genotypes (WT, HET, KO). In the confocal images and the membrane distribution 
analyzed here, transversal elements were more strongly represented than longitudinal 
elements for all three genotypes. These data match the obvious transversally striated pattern 
which is typical for confocal images of AMCM and represents the T-tubule system (transverse 
tubules) while longitudinal tubules are less frequent in confocal images of AMCM. Furthermore, 
the composite of the averaged peak values (0°±10°, 90°±10°) showed no significant change 
between the different genotypes (Fig. 34 B). 
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Fig. 34: Influence of p63RhoGEF deletion on the caveolin-3 localization in transverse and 
longitudinal tubules in AMCM. 
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Analysis of the caveolin-3 distribution in transverse and longitudinal tubules in isolated cardiomyocytes from 10-20 
week old male, wildtype (WT), heterozygous (HET) and knockout (KO) p63RhoGEF mice was performed. Cells 
were seeded on laminin coated glass coverslips in adequate amount and fixed after 1 h in culture. Confocal center 
view images were taken. A) The distribution of caveolin-3 at the sarcolemma and in the intracellular space was 
determined and is given in percent of the total signal. B) Representative confocal images show immunostaining for 
caveolin-3 (red) together with DAPI (blue) to visualize nuclei. Caveolin-3 images were processed with ImageJ to 
extract the membrane system (below) and used for further analysis (right) of the orientation. The obtained values 
for the distribution of caveolin-3 (A) as well as of the tubular orientation with 0°±10° (longitudinal tubules) and 
90°±10° (transverse tubules) (B) are given as means ± SEM, n=3, 15 cells per condition. 
As the overexpression of p63RhoGEF led to an increase in the Golgi apparatus particle 
number (Fig. 24), the impact of its deletion on the Golgi apparatus was studied next. AMCM 
from WT and p63RhoGEF-KO mice were isolated and the cis-Golgi protein GM-130 was 
detected by confocal immunofluorescence analysis (Fig. 35 A). By particle analysis, it could be 
demonstrated that in isolated AMCM the complete loss of p63RhoGEF resulted in a decrease 
in particle number as well as in particle size. The mean GM-130 signal was lower and the 
distribution analysis of GM-130 suggested that the fewer and smaller Golgi apparatus particles 
in KO-AMCM are slightly more confined to the perinuclear region (Fig. 35 B). 
 
Fig. 35: Influence of p63RhoGEF deletion on the Golgi apparatus morphology in AMCM. 
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Isolated adult mouse wildtype (WT) and p63RhoGEF knockout (KO) cardiomyocytes (AMCM) were cultured and 
then immunostained for GM-130. A) Representative center view confocal images are shown as overlays of GM-
130 (green) and DAPI (blue). The cell borders had been marked (yellow line) in ImageJ for better comparison. B) 
Analysis of the Golgi particle number (left) and the particle size (left middle) was performed with the help of the 
particle analysis tool of ImageJ. The intensity (right middle) and distribution (right) of GM-130 was analyzed by its 
fluorescence in the perinuclear region (selection of the nuclei with 2.5 µm enlargement) and in the rest of the cells. 
In total 10 cells per group were analyzed. The obtained values are shown individually, the means are indicated. 
Scale bar 25 µm. 
Due to the opposing effects of p63RhoGEF overexpression and deletion on the Golgi particle 
number, changes in the Golgi apparatus in TAC- compared to sham-AMCM were analyzed. 
This investigation was based on our previous finding that p63RhoGEF expression was 
increased in wildtype TAC hearts (refer to chapter 2, preliminary results). Therefore, sham- and 
TAC-AMCM were isolated and the cis-Golgi protein GM-130 detected by confocal 
immunofluorescence analysis (Fig. 36 A). In line with the identified role of p63RhoGEF in the 
regulation of the Golgi particle number, an increase in Golgi particle number could be 
determined in isolated TAC-AMCM. The particle size as well as the distribution of GM-130 was 
unchanged (Fig. 36 B). 
 
Fig. 36: Influence of TAC on the Golgi apparatus morphology in AMCM. 
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Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC). The cells were cultured and then immunostained for GM-130. A) Representative center view 
confocal images are shown. Representative center view confocal images are shown as overlays of GM-130 (green) 
and DAPI (blue). The cell borders had been marked (yellow line) in ImageJ for better comparison. B) Analysis of 
the Golgi particle number (left) and the particle size (right) was performed with the help of the particle analysis tool 
of ImageJ. The distribution (right) of GM-130 was analyzed by its fluorescence in the perinuclear region (selection 
of the nuclei with 2.5 µm enlargement) and in the rest of the cells. In total 25 cells from 3 different animals per group 
were analyzed. Values are given as means ± SEM, *p>0.05. Scale bar 25 µm. 
Finally, the size and shape of cell nuclei of sham- and TAC-AMCM were studied. Opposite to 
the observed changes in nucleus area in KO-AMCM, TAC-AMCM displayed an increase in the 
mean nucleus size. The shape of the nuclei was however unaltered (Fig. 37). 
 
Fig. 37: Influence of TAC on the nuclear morphology in AMCM. 
Adult mouse cardiomyocytes (AMCM) were isolated from animals 4 weeks after sham or transverse aortic 
constriction (TAC). The cells were cultured and then DAPI stained. The mean nucleus area (left) as well as their 
roundness (right) were quantified. Given are the means ± SEM, n=3, 120-180 cells per group in total, *p>0.05. 
  
  
  96 
5. Discussion 
5.1 Characterization of the GPCR-induced RhoA activation and localization in 
isolated adult mouse cardiomyocytes 
The monomeric G protein RhoA is an ubiquitously expressed protein having its main function 
in the modulation of the actin cytoskeleton in most cell types. In muscle cells, its role is best 
understood in smooth muscle cells. In these cells, RhoA acts as a regulator of contraction by 
augmenting the phosphorylation of the myosin light chain via its downstream signaling [106, 
159]. In striated muscle cells, however, there is still a lack of knowledge on its regulation and 
function, especially in the highly differentiated adult myocytes. 
With respect to cardiomyocytes, the role of RhoA had so far only been investigated in immature 
neonatal cells and in complex mouse models. Therefore, one aim of this thesis was to 
characterize the localization and activation of RhoA in isolated healthy and diseased adult 
cardiomyocytes. To address this aim, isolated adult mouse cardiomyocytes were used from 
healthy and pressure-overloaded hearts, and RhoA activity and localization were assessed by 
confocal immunofluorescence analysis with the help of an antibody recognizing the GTP-
loaded conformation of RhoA. The obtained results were exemplarily confirmed by biochemical 
analyses. In order to study the activation of RhoA, important cardiovascular GPCRs were 
activated which have been shown in the past to induce RhoA activation in neonatal 
cardiomyocytes and to play a role in pathological cardiac remodeling. 
The standard method to analyze RhoA activity uses a RhoA-binding domain (RBD), which 
specifically binds GTP-loaded RhoA. This biochemical assay can be performed with the help 
of a rhotekin-RBD fusion protein coupled to glutathione-S-transferase in a so called pulldown 
experiment with subsequent immunoblot analysis [160], or with a RBD-construct immobilized 
on a membrane with subsequent immunodetection of RhoA (commercially available G-Lisa 
system). A clear disadvantage of these biochemical approaches is their inability to give 
information on the spatial distribution of the RhoA activation in a certain cell type. Thus, in this 
thesis a monoclonal antibody was used, which recognizes the confirmation of GTP-loaded 
RhoA, combined with high resolution confocal imaging. This antibody has so far mostly been 
used to precipitate GTP-loaded RhoA from cell lysates and thus serves as an alternative to the 
RBD-based methods [161, 162]. Only rarely, the antibody was used for immunocytochemistry 
[151, 163]. Therefore, the initial results obtained with this antibody with respect to the 
localization and activation of RhoA in adult mouse cardiomyocytes were confirmed by 
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biochemical analyses to exclude experimental artifacts. Moreover, human adult atrial 
cardiomyocytes were used to confirm the localization of active RhoA detected in the mouse 
cardiomyocytes.  
 
Localization and activation of RhoA in healthy adult cardiomyocytes 
In summary, the data obtained in this thesis demonstrate that active RhoA is predominantly 
located at the sarcolemma in adult cardiomyocytes. This localization is species-independent 
as it was similar in mouse ventricular and human atrial cells (Fig. 5, Fig. 18). In some cells, a 
moderate accumulation of active RhoA in the former regions of the intercalated discs was 
detected (Fig. 5). By the staining of rarely occurring cell doublets, this localization could be 
confirmed (Fig. 5 E). In many but not all cells, a thin striated pattern of active RhoA was found 
inside the cell, which however, was only marginal compared to the strong sarcolemmal 
localization. To rule out any unwanted side-effects and damage due to cultivation, directly fixed 
AMCM and AMCM after 24 h in culture were compared (Fig. 7). While the faint sarcomeric 
pattern did not change, the intensity of the RhoA-GTP signals on the sarcolemma increased 
after 24 h in culture, indicating that RhoA activity might be initially suppressed by the cell 
isolation procedure or later activated due to the cell culture conditions. That active RhoA is 
associated to the plasma membrane via its C-terminal isoprenoid-group is a well-known fact 
and has been initially used to determine the activation status of the GTPase by analyzing its 
cytosol/membrane ratio [164]. In more recent publications, this activity dependent localization 
of RhoA had been confirmed with the help of FRET-based biosensors [165, 166]. Inactive RhoA 
mainly resides inside the cell, as its isoprenoid-group is covered by RhoGDI proteins [167]. In 
accordance, by using an antibody directed against a specific RhoA-epitope and not a certain 
RhoA confirmation, a predominant intracellular, sarcomeric localization in AMCM was detected 
(Fig. 5). Surprisingly, there was no overlap between the total RhoA and the active RhoA signal. 
A possible explanation could be the insensitivity of the total RhoA antibody. Indeed, by lysing 
the AMCM with a low stringent buffer containing sufficient detergent to solubilize the 
membranes, but insufficient salt to dissolve the sarcomere, the majority of RhoA was found in 
the insoluble fraction together with the sarcomeric protein α-actinin (Fig. 9). This suggested 
that only a very minor fraction of RhoA is active in adult cardiomyocytes. Alternatively, the total 
RhoA antibody might not detect membrane-associated active RhoA. This antibody was 
generated against an epitope which is located near the C-terminus of RhoA. Whether this 
might interfere with the conjugated isoprenoid group at the C-terminus and/or the membrane 
attachment is not clear. 
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To study the activation of RhoA in AMCM, three different ligands for GPCRs were used in this 
study: Endothelin-1 (ET-1) and angiotensin II (AngII) as well as the synthetic α-adrenoceptor 
agonist phenylephrine (PE). Based on our own data (preliminary results) and data from other 
groups, all three ligands were found to activate RhoA signaling in neonatal rat cardiomyocytes 
(NRCM) [117, 119]. Moreover, the signaling elicited by the corresponding GPCRs had been 
demonstrated to be involved in the pathogenesis of heart diseases, with the AngII type 1 
receptor being one of the most important pharmacological targets [168-170]. So far, the 
activation of RhoA by these ligands had not been demonstrated in adult cardiomyocytes. 
Therefore, a combination of ET-1 and PE was initially used in order to achieve maximal effects. 
AngII was not implemented in this pilot analysis due to its low effect on the RhoA activity in 
NRCM (Fig. 1, previous results). The impact of ET-1 and PE on cardiomyocyte signaling was 
investigated in three different ways. First, the phosphorylation of ERK1/2 as known 
downstream targets of ET-1 and PE was investigated [171, 172]. Second, the activation of 
RhoA was determined with the G-Lisa system, and third, the change in the active RhoA signal 
was assessed by confocal imaging with the help of the active RhoA antibody. Consistently, 
90 sec after addition of ET-1/PE an increase in ERK1/2 phosphorylation (Fig. 9 D) and an 
activation of RhoA in both experimental settings were found (Fig. 9 A). The advantage of the 
microscopic approach became obvious by the analysis of surface view images (Fig. 10). The 
amount of active RhoA was not simply increased at the sarcolemma, the protein also 
underwent a redistribution. In non-treated cardiomyocytes, active RhoA was detected in a 
moderate regular striated pattern with a striation width of around 0.9 µm. After application of 
the combination of ET-1/PE or of the single ligands, more cells displayed a pattern with a more 
pronounced signal width of 1.8 µm. By co-detection of the costamere via fluorescently-labeled 
phalloidin and of the M-band associated myomesin, it became clear that especially the active 
RhoA in or close to the costamere increased. Analysis of the cell morphology excluded that 
this effect was based on cell shrinkage or other morphological disturbances (Fig. 8). 
The costamers of cardiomyocytes have several important functions. They link the sarcomere 
via its outermost Z-disc to the sarcolemma, they hold focal adhesion complexes which are 
important for cell-matrix interaction, and they are hot spots of mechanosignaling (reviewed in 
[173]). A central protein in the costamere is dystrophin [174]. In order to determine the exact 
localization of active RhoA, co-localization analysis of dystrophin and active RhoA was 
performed (Fig. 5). Surprisingly, both proteins resided in different compartments at the 
sarcolemma, which would argue against a costameric localization of active RhoA. However, in 
the initial description of costameres in cardiomyocytes presented by Pardo and colleagues, 
the organization of these structures were described as rib-like bands above the Z-disc [175]. 
This was not the case for the localization of dystrophin in the investigated AMCM. Here, 
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dystrophin showed a dotted irregular pattern, which was not confined to the Z-disc (Fig. 5). In 
contrast, activated RhoA was organized in a rib-like pattern with increasing intensities above 
the Z-disc upon GPCR activation (Fig. 8, Fig. 10). Further analyses are needed to clarify the 
exact localization of active RhoA in this sarcolemmal region. 
Another important signaling hot spot in cardiomyocytes are caveolae. In these flask-shaped 
invaginations in the outer sarcolemma and in the transverse and longitudinal tubular system 
of cardiomyocytes, important signal components are clustered allowing their tight control [61, 
176]. In neonatal cardiomyocytes, the role of caveolae for RhoA regulation had already been 
demonstrated. Anastasi and colleagues showed that the disruption of caveolae by cholesterol-
depletion with methyl-β-cyclodextrin (MβCD) resulted in a blunted RhoA activation in response 
to stretch in NRCM. Moreover, they demonstrated that a substantial amount of RhoA is located 
in caveolae [49]. Comparable effects were described for the leptin-induced RhoA activation in 
NRCM. Interestingly, in this work the authors demonstrated that RhoA was absent from the 
caveolae without leptin and translocated into the caveolae within 5 min after leptin application 
[177]. Based on these findings, and the different patterns observed for dystrophin and active 
RhoA, the co-localization of active RhoA and caveolin-3 at the surface of AMCM was 
investigated (Fig. 6). However, the determined co-localization coefficients for both proteins 
were rather low. In summary, caveolin-3 showed a slightly better correlation with active RhoA 
than vice versa. The determined Pearson correlation coefficient was ~0.1, arguing against a 
general co-localization of both proteins. 
 
Localization and activation of RhoA in diseased adult cardiomyocytes 
As mentioned above, an important part of this thesis was to compare RhoA signaling in healthy 
and diseased cardiomyocytes. As a model system, murine adult cardiomyocytes were used, 
which offer the possibility to study healthy and diseased cardiomyocytes with the same genetic 
background. Moreover, the usage of mice as cell donors has the advantage of obtaining 
cardiomyocytes with a defined cellular disease phenotype. In this study, mice were subjected 
to transverse aortic constriction (TAC) which initially led to compensated hypertrophy and 
subsequently to decompensated heart failure as demonstrated by the reduction in the 
contractile performance and the ventricular dilation (Fig. 11). Moreover, the isolated 
cardiomyocytes were significantly thicker and longer compared to sham cells (Fig. 12), 
indicating that decompensated, eccentric hypertrophy was present at the end of the TAC 
experiment [178]. The TAC model was also chosen because RhoA had been demonstrated to 
be chronically activated in TAC hearts. Increased RhoA activation was found as early as 24 h 
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after TAC and lasted at least for up to one year [114]. Thus, the TAC model combined the 
advantages of a controlled disease progression with a relatively low mortality, and a very broad 
time window in which the pathological change in RhoA activity occurred. Importantly, the 
feasibility of using isolated adult cardiomyocytes to analyze disease-dependent changes in 
signal transduction had been demonstrated by others before [87, 179]. 
One goal of this part of the thesis was to obtain insight into the currently unknown localization 
of active RhoA in diseased cardiomyocytes. Confocal imaging and analysis of its pattern 
regularity revealed that together with the patterns of dystrophin and caveolin-3, also the pattern 
of active RhoA became less organized at the surface of AMCM four weeks after TAC (Fig. 14). 
As all three proteins were found to reside in different membrane compartments, this finding 
argues for a general disturbance of the sarcolemmal organization in diseased cardiomyocytes. 
This is in line with data on the distribution of dystrophin and on the general topography of the 
sarcolemma in diseased cardiomyocytes. For dystrophin, an abnormal distribution had been 
described in the diseased human myocardium with a loss of the normal punctate pattern at the 
sarcolemma [180]. Data obtained by scanning ion conductance microscopy revealed that in 
diseased human and rat cardiomyocytes a loss of the TT and Z-groove organization of the 
sarcolemma occurred [57, 61]. 
Besides the differences in RhoA localization and regularity, the ability of the different GPCR 
agonists to activate RhoA was significantly altered in AMCM after TAC. First, the basal activity 
of RhoA in TAC-AMCM was significantly higher as in sham-AMCM. This increase was not due 
to an increase in cell size, as all values were normalized to the cell area, and also not due to 
an increase in RhoA expression (Fig. 16). In contrast, a reduction in the total amount of the 
protein was found. Previous studies suggested that RhoA expression is increased in the 
diseased heart [181, 182]. However, individual cell type analysis was never performed before. 
In the diseased heart, a change in the cellular composition takes place, e.g. the number of 
myofibroblasts increases, which express high levels of RhoA [183]. Second, the application of 
the GPCR ligands did not induce any further augmentation of the RhoA activity. In contrast, 
ET-1 and PE even decreased the activity of RhoA after TAC (Fig. 15). Although, at the current 
status this cannot be finally explained, different mechanisms can be proposed. First, the 
corresponding receptors are desensitized in the setting of TAC due to the high neurohumoral 
stimulation. This is a well-known phenomenon, which has been demonstrated before for the 
AT1R, the α-adrenergic as well as the endothelin-1 receptors in cardiomyocytes [184-186]. 
Second, the disturbances in the membrane organization disrupt the corresponding signaling 
complexes, which has been nicely documented for the α2-adrenoceptor [87]. Third, changes in 
the expression of accessory RhoA regulators occurred. A potential candidate in this scenario 
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is the RhoA-specific p190B-RhoGAP (alias ARHGAP5). According to preliminary RNA 
sequencing data from our lab, this GAP is strongly downregulated in hearts from mice after 
TAC and might thus explain the unleashed RhoA activity. 
To further study the mechanisms underlying the changes in RhoA activity and activation in 
TAC-AMCM, the effect of the cholesterol-depleting reagent MβCD was investigated. 
Interestingly, this led to the same increase in basal RhoA activity as found in the TAC-AMCM 
(Fig. 17), although active RhoA did not reside in caveolae in AMCM. Moreover, the application 
of ET-1 to the cells resulted in the same decrease in RhoA activity as in the TAC-AMCM (Fig. 
17 C). These data clearly argue that the disturbance of the sarcolemmal organization is a likely 
explanation for the changes observed in TAC-AMCM and MβCD-treated AMCM. The 
desensitization of the ET-1 receptor can be ruled out as a cause in the MβCD-treated AMCM. 
5.2 Characterization of the localization of the guanine nucleotide exchange factor 
p63RhoGEF in isolated adult mouse cardiomyocytes 
The guanine nucleotide exchange factor p63RhoGEF was first identified by Souchet and 
colleagues in 2002. By Northern blot analysis , they and others demonstrated that this GEF is 
expressed in the human heart and brain [144, 187]. Later studies revealed that the protein is 
also expressed in other tissues like the vasculature [149, 150]. 
In the initial characterization of p63RhoGEF, its localization was studied in the human 
myocardium and a sarcomeric, I-band associated localization was postulated [187]. In a later 
study, p63RhoGEF was found predominantly at the sarcolemma and in fine intracellular 
striations in the adult mouse myocardium [142]. In order to verify the localization of 
p63RhoGEF in AMCM and due to the lack of available antibodies recognizing the native protein 
in immunocytochemical studies, an adenoviral overexpression approach was used. The 
human 580 amino acid p63RhoGEF variant as well as the N-terminally truncated p63∆N 
construct were overexpressed in AMCM and their localization was studied by confocal imaging 
based on the additional N-terminal c-myc-tag. The truncation of p63RhoGEF by the first 294 
amino acids (p63∆N) has two consequences for the function of the protein. One lays in the 
missing cysteine stretch in the N-terminus, which is found in the 580 amino acid full length 
protein. This stretch was demonstrated to be modified by S-palmitoylation leading to the 
membrane attachment of p63RhoGEF [136]. Moreover, in p63∆N most of the catalytic DH-
domain is missing. As the C-terminal extension of the PH domain is present in this construct, 
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p63∆N is still able to interact with active Gαq and functions downstream as a dominant negative 
molecule, not only for RhoA but also for other Gαq-elicited pathways [154]. 
In general, the localization of both proteins was dependent on the transduction efficiency of 
the AMCM. In cells with a lower expression, full length p63RhoGEF localized mainly in the 
perinuclear region and in randomly distributed intracellular speckles. When the protein was 
higher expressed, an additional strong sarcolemmal association was found (Fig. 19 A). This 
difference in low and high expressing cells could also be interpreted as a time-dependent effect 
as the onset of p63RhoGEF expression in highly transduced cells is faster than in lowly 
transduced. This would mean that p63RhoGEF is first targeted to the membrane system in the 
perinuclear region, then becomes palmitoylated there, and is finally transported outward to the 
sarcolemma. How p63RhoGEF gets palmitoylated is completely unknown. More than 20 
mammalian palmitoyltransferases had been identified based on their sequence, which localize 
either in the membranes of the endoplasmic reticulum, the Golgi apparatus or in the plasma 
membrane [188]. None of these proteins had been investigated in cardiomyocytes so far. 
However, the importance of the palmitoylation of p63RhoGEF can be appreciated by 
comparing its localization with the one of p63∆N. This construct mainly resides in the 
sarcomere in low expressing cells and in high expressing cells an additional prominent 
localization in the region of the former intercalated disc occurred (Fig. 19 B). The latter is rather 
unexpected as this accumulation could only be due to protein-protein interaction and not due 
to membrane targeting via a lipid modification. Why full length p63RhoGEF did not show an 
accumulation in the intercalated disc is not clear, but suggests that the lipid-anchored protein 
might not be able to get in close contact with the potential interaction partner of p63∆N. This 
raises the question for future studies whether the different p63RhoGEF splice variants, with or 
without palmitoylation, might have different functions in cardiomyocytes. 
Although p63RhoGEF did not accumulate at the former intercalated disc, it also did not spare 
this region. This finding together with the localization of active RhoA in the intercalated disc 
(Fig. 5) indicates that this region of the cell might be of special importance with respect to RhoA 
signaling. In line, the intercalated disc had been suggested before to be a place of RhoA 
signaling by the characterization of Myozap. This protein was found in the intercalated discs of 
adult mouse cardiomyocytes, the adult myocardium, and was shown to be an activator of RhoA 
signaling in HEK293 cells and in NRCM [189, 190].  
The dominant localization of full length p63RhoGEF in membranous structures was further 
characterized by co-localization analyses. As in caveolae palmitoylated proteins were found to 
be enriched [189, 191], the co-localization of caveolin-3 and p63RhoGEF was studied first 
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(Fig. 22). In cells with low p63RhoGEF expression the overall correlation of both proteins in 
center view images was low with a Pearson’s coefficient of 0.3. The Manders’ coefficients 
demonstrated that the overlap between p63RhoGEF and caveolin-3 is higher than vice versa 
(Fig. 22 B). This was mainly due to their common localization in the perinuclear region. 
Interestingly, independent of the height of the overexpressed p63RhoGEF, more caveolin-3 
was found in the perinuclear region than in control-transduced cells (Fig. 22 D). This suggests 
that p63RhoGEF potentially influences the transport of caveolin-3 from its synthesis place at 
the ER to the caveolae. In cells with high p63RhoGEF expression, the overall correlation of 
both proteins in center view images was higher with a Pearson’s coefficient of 0.7. This could 
be explained by their common localization in the perinuclear region and in the sarcolemma 
(Fig. 22 B). However, it has to be taken into account that the z-resolution in confocal imaging 
is always worse than the x,y-resolution. This can lead to a false-positive overlap of signals 
having the same x,y-positioning but localizing in a different z-depth. Therefore, surface view 
images were taken from the transduced cells (Fig. 22 C). In principle this bears the same 
problem. However, the analyzed proteins in this thesis, like active RhoA and p63RhoGEF, were 
dominantly located at the sarcolemma and thus the cytosolic signal noise underneath the 
sarcolemma was relatively low. The difference between both image modalities is nicely 
demonstrated by the fact that by analyzing surface view images the obtained correlation 
coefficients of caveolin-3 and p63RhoGEF were considerably lower than those obtained from 
center view images (Fig. 22 B, C). In summary, the co-localization of p63RhoGEF and 
caveolin-3 at the sarcolemma was not prominent. In former studies, our group had already 
shown that the AngII-dependent, p63RhoGEF-driven RhoA activation in smooth muscle cells 
could not be disturbed by the depletion of cholesterol and is thus not dependent on caveolae 
[150]. 
The first contact of membrane-associated proteins with the membranous system often takes 
place at the ER. In order to analyze the accumulation of p63RhoGEF in the perinuclear region, 
and thus in the rough ER, co-localization analyses of full-length p63RhoGEF and p63ΔN were 
performed together with an antibody recognizing proteins with the ER retention and targeting 
motif KDEL (lysine - aspartic acid - glutamic acid - leucine). This motif is found in many soluble 
ER proteins at the C-terminus and is detected by a family of GPCR-like receptors, the KDEL-
receptors [192-194]. These receptors mainly reside in the cis-Golgi compartment and bind the 
escaped ER KDEL-proteins. This induces the retrograde transport of the receptor with its 
ligand to the ER. In the ER, the binding between the receptor and the KDEL protein is released 
due to the shift in the pH between the Golgi and the ER [195]. 
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Surprisingly, in p63RhoGEF-overexpressing cells the localization of p63RhoGEF was almost 
completely mimicked by the anti-KDEL-antibody (Fig. 23 A). This led to positive KDEL-signals 
in membrane compartments where soluble KDEL-proteins normally do not reside, like in the 
sarcolemma. Moreover, compared to control transduced cells the overall signal intensity given 
by the KDEL-antibody was extraordinarily high in cells expressing either p63RhoGEF or 
p63ΔN. This all pointed to an experimental artefact as explanation for the more than 
unexpected finding. Therefore, immunoblot analyses of the transduced cells were performed 
with the KDEL-antibody, showing that the antibody could recognize the overexpressed 
p63RhoGEF constructs (exemplarily shown for p63ΔN in Fig. 23 C). The KDEL antibody used 
in this study (Abcam #ab176333) is supposed to recognize the six amino acid long antigen 
SEKDEL (serine - glutamic acid - lysine - aspartic acid - glutamic acid - leucine, personal 
communication with Abcam). However, it can be hypothesized that this antibody in addition 
recognizes the C-terminal EDEL motif of p63RhoGEF since that motif differs from the KDEL 
motif by only one amino acid. 
Although based on this artefact, no insight was obtained on the localization of p63RhoGEF at 
the ER, further information could be gained on the structure of p63ΔN in the cytoskeleton and 
the intercalated disc. The KDEL antibody did not detect p63ΔN when it was localized at the 
sarcomere, only its localization at the intercalated discs was detected by the KDEL antibody. 
Since it is hypothesized that the KDEL antibody detects the EDEL motif of p63RhoGEF, two 
explanations for the observed phenomenon are possible: i) the C-terminal EDEL motif of 
p63ΔN is not accessible to the antibody when the protein is localized in the sarcomere; ii) the 
proportion of p63ΔN, which is localized in the sarcomere does not possess its C-terminus 
(Fig. 38). Based on former experiences with this construct the second explanation is more 
likely as the C-terminus of p63RhoGEF is relatively unstructured and labile [116]. Especially in 
truncated versions like p63ΔN it can easily break (personal communication with S. Lutz). If this 
explanation is correct, it can be concluded that the likelihood of the existence of a sarcomeric 
p63RhoGEF splice variant is low because so far, no p63RhoGEF splice variant with a missing 
C-terminus was characterized. 
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Fig. 38: Cartoon illustrating the potential binding modalities of the KDEL antibody to the N-
terminally truncated p63RhoGEF. 
Next, the co-localization of p63RhoGEF with the Golgi apparatus was analyzed (Fig. 24). For 
this, the cis-Golgi matrix protein GM-130 was detected together with full length p63RhoGEF 
and p63∆N. The latter showed no co-localization with GM-130. But the full length protein and 
GM-130 were both found in close vicinity in the perinuclear region and in randomly distributed 
speckles in the cell. In general, the GM-130-containing Golgi particles, which had a mean size 
of around 0.6 µm2, were rather confined independent of their localization. The overlap of GM-
130 and p63RhoGEF was not prominent and the compartments in which both proteins resided 
appeared to be associated to each other. The knowledge on the Golgi apparatus in 
cardiomyocytes is surprisingly sparse. The speckled distribution had been demonstrated 
before in isolated rat cardiomyocytes with GM-130 as a marker protein [196]. The ultrastructure 
and organization of these speckles is not known. Based on the rather similar morphology of 
the Golgi apparatus in cardiac and skeletal myocytes, one could hypothesize that p63RhoGEF 
is located in the trans-Golgi network. For skeletal myocytes it was demonstrated by electron 
microscopy that each Golgi apparatus was a stack of three to four cisternae, with a height of 
around 0.7 µm. Immunolabeling revealed that these small stacks are polarized with the cis-
Golgi side facing the nucleus [197]. A further argument for this hypothesis comes from one of 
our previous studies in cardiac fibroblasts. In these cells we could show that p63RhoGEF co-
localized with the trans-Golgi network protein GOPC, but not with the cis-Golgi protein GM-
130 [151]. As unfortunately, the GOPC staining in AMCM did not result in a reliable signal and 
the Golgi apparatus is so small in these cells, further analyses are needed with other Golgi 
markers and super resolution microscopy to shed light on the exact localization of p63RhoGEF 
in the adult cardiomyocyte Golgi apparatus. 
Taken together, the localization studies performed in this thesis confirm the identified 
sarcolemmal-associated location of endogenous p63RhoGEF in the adult myocardium, which 
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had been described by Smith and colleagues [142]. Moreover, its localization at secretory 
endomembrane was found in AMCM similar as this was described for cardiac fibroblasts by 
our group [151]. The localization in the sarcomeric I-band that had been described by Souchet 
and colleagues could not be verified [187]. 
5.3 Characterization of the function of the guanine nucleotide exchange factor 
p63RhoGEF in isolated adult mouse cardiomyocytes 
In order to get more insight into the function of p63RhoGEF in adult cardiomyocytes, three 
models were compared. On the one hand a gain-of-function model by adenoviral 
overexpression was used, on the other hand a loss-of-function model by heterozygous or 
homozygous knockout of p63RhoGEF was investigated. Moreover, AMCM from diseased 
hearts were analyzed as p63RhoGEF was found to be increased under this condition [151]. All 
three models clearly had their limitations. In the gain-of-function model, the culture of the 
adenovirally-transduced cells did not any longer allow the analysis of the RhoA activity. The 
used AMCM were isolated from a global, constitutive and not a cell-type specific, inducible 
mouse model, which can lead to adaptive processes during the development. The changes 
seen in TAC-AMCM are based on manifold changes in signaling and are not only due to one 
single signal cascade. Nonetheless, by comparing all three models, insights in the role of 
p63RhoGEF in adult cardiomyocytes could be obtained. 
 
Does p63RhoGEF activate RhoA in adult cardiomyocytes? 
One of the most important question in this context was if p63RhoGEF is a mediator of the 
GPCR-driven RhoA activation in adult cardiomyocytes. As shown in the preliminary data, in 
neonatal cardiomyocytes its knockdown and its overexpression resulted in a clear reduction 
and augmentation of the ET-1-induced RhoA activation (Fig. 1). In adult cardiomyocytes, the 
obtained results were much more complex. As the adenoviral transduction of the AMCM did 
not allow any analysis of RhoA activation, insights could only be gained by the knockout model. 
Here, the comparison of the heterozygous (HET) and homozygous (KO) knockout AMCM is of 
utmost importance. In both AMCM types, the responsiveness of RhoA to the investigated 
GPCR ligands was gone, which would argue for a prominent role of p63RhoGEF in the 
underlying signaling (Fig. 33). But in the KO-AMCM, the basal RhoA activity was increased as 
shown by directly fixed and cultured cells (Fig. 32). This fully mimicked the situation in TAC- 
and MβCD-treated AMCM and cannot be simply attributed to the role of p63RhoGEF as a 
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mediator of the Gq/11-dependent RhoA activation. The data indicate that p63RhoGEF has an 
additional effect in AMCM, which becomes only prominent by its full deletion, and is in line with 
the differences seen in the corresponding mouse models. Here, after TAC, a worsening of the 
contractile function was found only in HET-mice but not in KO-mice (refer to preliminary 
results). Instead the mortality of the KO-mice was tremendously increased (Fig. 3). Thus, it 
could be concluded that p63RhoGEF plays a role in the GPCR-induced RhoA activation in 
adult cardiomyocytes but has an additional effect on the signaling organization. Whether the 
additional function relies on a so far unclear role of p63RhoGEF in these cells, or if it is a 
consequence of the missing competition between p63RhoGEF and other Gq/11 signaling 
pathways, like the activation of phospholipase Cβ and PKC is not clear. 
By comparison of data obtained in this thesis as well as of data obtained in the parallel 
p63RhoGEF-KO TAC study (Thesis of Dr. Anita Ongherth) with a study on the impact of the 
cardiomyocyte-specific deletion of RhoA during pressure overload some interesting common 
themes can be identified. The loss of RhoA resulted in an enhanced dilatation of the left 
ventricle after TAC and a worsened contractile function similar as demonstrated for the 
p63RhoGEF-HET mice (see preliminary results). Interestingly, the loss of RhoA resulted in an 
increased basal phosphorylation of PLCβ and PKC, suggesting that there is a close link 
between RhoA signaling and the canonical Gq/11 signaling in cardiomyocytes. After an acute 
stimulus of 10 min of TAC, the increased phosphorylation of both proteins was reduced, 
whereas it was increased in the corresponding WT animals. The authors explained this finding 
by a similarly directed, 2-fold change in the expression level of the phosphatase and tensin 
homolog (PTEN), which cleaves PIP3 into PIP2 and thus might be able to directly influence 
PLCβ activity [124]. However, 10 min is a rather short time for such a strong regulation of the 
total level of a protein. Alternatively, this could be explained by a less dominant p63RhoGEF 
signaling under basal conditions when RhoA is depleted, and a still possible competition of 
p63RhoGEF with PLCβ signaling when Gq/11 is activated. The Gq protein, p63RhoGEF and 
RhoA are all lipid-anchored proteins and might reside in a pre-complex at the sarcolemma 
[116, 198]. It was demonstrated that the complex has a certain basal activity, which is 
dependent on its membrane localization [136]. In case when RhoA is missing, this might lead 
to a preferential pre-coupling of Gαq to PLCβ. PLCβ and p63RhoGEF in principle interact with 
the same site in Gαq, but the RhoA-p63RhoGEF-Gαq complex is supposed to be more offset 
from the membrane than the PLCβ-Gαq complex and thus the missing RhoA could indeed 
induce changes in pre-coupling and in basal signaling due to the interference with the 
membrane offset of Gαq [198]. However, upon GPCR activation, interaction of Gαq with 
p63RhoGEF could be still possible, but results in non-productive signaling as well as in a 
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competition with PLCβ. One further argument for a role of the missing competition between 
p63RhoGEF and other Gq/11 signaling pathways as a cause of the observed effects in KO-
AMCM and KO-mice comes from a mouse model in which the activation of PKCα was studied 
for the heart function. Interestingly, the activation of PKCα caused a complete uncoupling of 
the β-adrenoceptors but had no impact on the heart/body weight ratio and contractile function 
in young mice. Moreover, PKC activation on the background of enhanced Gαq-signaling, like 
in a Gαq-overexpressing mouse, dramatically increased the mortality especially in male mice 
[199]. 
In summary this suggests that in the heterozygous p63RhoGEF knockout mice, the effects 
mainly rely on the diminished RhoA activation, whereas in homozygous knockouts a mixed 
answer of a blunted RhoA activation and an induced PLCβ/PKC activation occurred. The latter 
may play role in the heterologous desensitization of the GPCRs as this was e.g. demonstrated 
for the AT1R in NRCM [185]. But also an impaired membrane organization could account for 
the changes in RhoA activity in KO-AMCM, similar as in TAC and MβCD-treated AMCM. 
 
Does p63RhoGEF play a role in the regulation of adult cardiomyocyte growth and nucleus 
size? 
RhoA was initially proposed as a pro-hypertrophic factor in cardiomyocytes [124], but diverse 
mouse models argued against its role in the typical concentric heart growth. Changes in RhoA 
activity and expression in cardiomyocytes were either associated with a dilated phenotype 
[122, 124] or no with changes at all [123]. Similar results were obtained for p63RhoGEF. In the 
intact mouse heart, no differences in the cardiomyocyte size of the HET- compared to WT-
mice was found, although the mice showed a slight ventricular dilation (Thesis Dr. Anita 
Ongherth). In the KO-mice, the geometry of the heart was not changed compared to WT-
hearts, but the cardiomyocytes had a slightly smaller diameter (Fig. 29, 31). Isolation of these 
cells revealed that the KO-AMCM seemed to have also a decreased diameter, reflected by the 
analyzed cell depth. Culturing further decreased cell depth more pronounced in KO-AMCM 
than in the other two genotypes (Fig. 29). In contrast, cells which overexpressed p63RhoGEF 
were slightly longer, but showed no differences in cell depth and width (Fig. 25). This 
demonstrates that p63RhoGEF has no dramatic effect on the AMCM size but might support 
their stabilization at least in culture. 
However, one interesting morphological finding was the difference in the mean nucleus area. 
AMCM overexpressing the dominant negative p63ΔN constructs and cells with a full depletion 
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of p63RhoGEF showed a significantly smaller mean nucleus area than control-transduced and 
WT cells. (Fig. 27, Fig. 30, 31). This phenotype was also present in the intact myocardium 
(Fig. 31). In contrast, in TAC-AMCM the nuclei were significantly bigger than in sham cells 
(Fig. 37), but p63RhoGEF overexpression was not sufficient in increasing the size of the nuclei 
(Fig. 27). How the size of the nucleus is regulated in cardiomyocytes is not known. An increase 
in nuclear size had been described for example in tissues from patients with doxorubicin-
induced cardiotoxicity [200]. In general it is thought that the nuclear and cell volume are related 
to each other and the size expansion of a nucleus is restricted [201]. Factors that might 
regulate the nuclear size are the DNA content [202] and extra-nuclear factors [203]. One 
hypothesis suggests that the membrane synthesis occurring in the ER membrane is the limiting 
factor for the nucleus growth [204] and that so called reticulon proteins might be involved in 
growth control [205]. An even open question is if a difference in nucleus size can influence cell 
behavior. In this context, at least a correlation between the nucleus size and transcriptional 
activity had been described [206]. Diseased cardiomyocytes resemble some of these proposed 
features. Growth in cell size is accompanied by an increase in nucleus size, and the 
transcriptional activity is clearly increased in the hypertrophic cardiomyocyte. Most 
interestingly, in a comparative study of 5 different cardiac hypertrophy mouse models, only 5 
common genes were found to be dysregulated. Amongst these, was the upregulated 
reticulon 4 [207]. This, however, does not explain the smaller nuclei in the p63RhoGEF-KO 
model. Further studies are needed to unravel the mechanism and to characterize the 
consequences of this morphological abnormality. 
 
Does p63RhoGEF have an influence on endomembrane systems in adult cardiomyocytes? 
In all three model systems used in this thesis, changes in the endomembrane system were 
detected. Amongst these, the most conclusive was the change in the Golgi apparatus. An 
increase in p63RhoGEF, as obtained by adenoviral transduction and observed in TAC hearts, 
increased the number of GM-130-positive particles, whereas the knockout of p63RhoGEF 
decreased the number of particles (Fig. 24, Fig. 35, Fig. 36). Also, here it is not clear how 
p63RhoGEF could play a role in this scenario. The two likeliest explanations are: First, this 
regulation is RhoA-dependent. A link between RhoA and the Golgi regulation had been 
published several times [183, 208]. However, this would be a secondary and not a direct effect 
since active RhoA was not detected at the Golgi particles in AMCM under any condition, as it 
was demonstrated before by others [209]. Second, p63RhoGEF interferes with the described 
KDEL-receptor induced Gαq/11 activation. It was shown that depletion of Gαq/11 inhibited the 
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transport of cargo from the Golgi to the plasma membrane. As a consequence, the cargo got 
stuck in the Golgi apparatus. As a potential mechanism the KDEL receptor-induced, Gαq/11-
mediated activation of Src kinases was postulated [210]. How Gαq/11 activates Src kinases was 
not further elucidated. Therefore, a remaining open question is if p63RhoGEF competes with 
this signaling as it competes with PLCβ. 
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